Antibodies and chimeric antigen receptors targeting TACI

By developing antibodies and CARs that target TACI, the challenge of BCMA antigen escape in therapies is addressed, improving treatment outcomes for cancers and autoimmune disorders through enhanced cytotoxic T cell responses.

JP7584453B2Active Publication Date: 2024-11-15THE GENERAL HOSPITAL CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021571870
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-04-20
Filing Date
2020-06-04
Publication Date
2024-11-15
Estimated Expiration
2040-06-04

AI Technical Summary

Technical Problem

Current therapies targeting BCMA for diseases like multiple myeloma face challenges due to antigen escape and resistance, necessitating alternative targets for effective treatment.

Method used

Development of antibodies, antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptors (CARs) specifically designed to target TACI, which interact with TACI to induce cytotoxic T cell responses against target cells, including those expressing TACI.

Benefits of technology

These agents effectively overcome BCMA antigen escape by targeting TACI, enhancing therapeutic efficacy in treating cancers and autoimmune disorders by promoting cytotoxic T cell activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584453000010
    Figure 0007584453000010
  • Figure 0007584453000011
    Figure 0007584453000011
  • Figure 0007584453000012
    Figure 0007584453000012
Patent Text Reader

Abstract

The present invention provides antibodies, antibody-drug conjugates, bispecific T-cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, for example, in methods for treating cancer (e.g., multiple myeloma), autoimmune disorders (e.g., characterized by high titers of disease-contributing antibodies), or plasma cell dyscrasia disorders (e.g., plasma cell dysplasias) in a subject in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [Related Applications] This application claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 856,998, filed June 4, 2019, entitled "ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING TACI," U.S. Provisional Application No. 62 / 907,930, filed September 30, 2019, entitled "ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING TACI," and U.S. Provisional Application No. 63 / 012,735, filed April 20, 2020, entitled "ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING TACI," the entire contents of each of which are incorporated herein by reference. [Background technology]

[0002] Chimeric antigen receptors (CARs) induce cytotoxic T cell responses against target cells expressing a selected target antigen, most often a tumor antigen or tumor-associated antigen. CARs are adaptations of T cell receptors in which the antigen-binding domain is replaced with the antigen-binding domain of an antibody that specifically binds to the induced target antigen. For example, engagement of a target antigen on the surface of a target cell by a CAR expressed on a T cell ("CAR T cell" or "CAR-T") promotes killing of the target cell. Summary of the Invention

[0003] Described herein are antibodies, antibody drug conjugates, bispecific T cell engagers (BiTEs), and chimeric antigen receptors (CARs) that target transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), which may be useful for treating a subject having a disease or disorder, e.g., cancer, a plasma cell dyscrasia or disorder, or an autoimmune disease or disorder.

[0004] Some aspects of the present disclosure provide an antibody that specifically binds to transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), (i) heavy chain complementarity determining region 1 (CDR-H1), heavy chain complementarity determining region 2 (CDR-H2), and heavy chain complementarity determining region 3 (CDR-H3) of a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1; and / or (ii) An antibody is provided, comprising a light chain variable region (VL) comprising light chain complementarity determining region 1 (CDR-L1), light chain complementarity determining region 2 (CDR-L2), and light chain complementarity determining region 3 (CDR-L3) having the amino acid sequence of SEQ ID NO:2.

[0005] In some embodiments, the antibody comprises: (i) CDR-H1 set forth in SEQ ID NO: 26, CDR-H2 set forth in SEQ ID NO: 27, and CDR-H3 set forth in SEQ ID NO: 28; CDR-L1 set forth in SEQ ID NO: 29, CDR-L2 set forth in SEQ ID NO: 30, and CDR-L3 set forth in SEQ ID NO: 31; (ii) CDR-H1 as set forth in SEQ ID NO: 32, CDR-H2 as set forth in SEQ ID NO: 33, and CDR-H3 as set forth in SEQ ID NO: 34; CDR-L1 as set forth in SEQ ID NO: 35, CDR-L2 as set forth in SEQ ID NO: 36, and CDR-L3 as set forth in SEQ ID NO: 31; or (iii) CDR-H1 set forth in SEQ ID NO: 37, CDR-H2 set forth in SEQ ID NO: 38, and CDR-H3 set forth in SEQ ID NO: 39; CDR-L1 set forth in SEQ ID NO: 40, CDR-L2 set forth in SEQ ID NO: 30, and CDR-L3 set forth in SEQ ID NO: 41 Includes.

[0006] In some embodiments, the antibody has a K of about 2 nM or less. D and in some cases, the antibody binds to TACI with a K between about 500 pM and about 1 nM. D and optionally, the antibody binds to TACI with a K between about 700 pM and about 900 pM. DIn some embodiments, the antibody binds to TACI with a K of about 861 pM. D It binds to TACI.

[0007] In some embodiments, the antibody comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1 and / or a light chain variable domain (VL) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2. In some embodiments, the VH comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:1 and the VL comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:2. In some embodiments, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2.

[0008] In some embodiments, the antibody is a monoclonal, human, humanized, or chimeric antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody is an antibody fragment that specifically binds to TACI. In some embodiments, the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments. In some embodiments, the antibody is an IgG antibody, optionally an IgG1 antibody. In some embodiments, the antibody is an scFv. In some embodiments, the scFv comprises an amino acid sequence that is at least 85% identical to SEQ ID NO:4 or SEQ ID NO:5. In some embodiments, the scFv comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5. In some embodiments, the scFv is fused to an Fc.

[0009] Another aspect of the invention described herein pertains to a composition comprising any one of the antibodies described herein.

[0010] Another aspect of the invention described herein pertains to a polynucleotide encoding any one of the antibodies described herein.

[0011] Another aspect of the invention described herein pertains to a vector comprising any one of the polynucleotides described herein.

[0012] Another aspect of the invention described herein pertains to a host cell comprising any one of the vectors described herein.

[0013] In one embodiment, the host cell is a mammalian cell. In one embodiment, the mammalian cell is a Chinese Hamster Ovary (CHO) cell.

[0014] In another embodiment, the host cell is a prokaryotic cell, hi one embodiment, the prokaryotic cell is E. coli.

[0015] Another aspect of the invention described herein relates to a method for producing an antibody that specifically binds to TACI, comprising culturing any one of the host cells described herein in a culture medium. In one embodiment, the method further comprises recovering the antibody from the host cell or culture medium.

[0016] Another aspect of the invention described herein relates to an antibody drug conjugate comprising any one of the antibodies described herein.

[0017] Another aspect of the presently described invention relates to a chimeric antigen receptor (CAR) polypeptide comprising an extracellular target binding domain, the extracellular target binding domain comprising a TACI binding domain.

[0018] In one embodiment, the CAR polypeptide comprises a transmembrane domain and an intracellular signaling domain.

[0019] In one embodiment, the CAR polypeptide further comprises one or more costimulatory domains.

[0020] In one embodiment, the TACI binding domain does not include APRIL, BAFF, CAMLG, or portions thereof.

[0021] In one embodiment, the TACI binding domain has a K of about 2 nM or less. D In one embodiment, the TACI binding domain binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the TACI binding domain binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the TACI binding domain binds to TACI with a K of about 861 pM. D It binds to TACI.

[0022] In one embodiment, the TACI binding domain comprises an antibody or an antigen-binding fragment thereof.

[0023] Another aspect of the presently described invention relates to a CAR polypeptide comprising an extracellular target binding domain comprising any one of the antibodies described herein or an antigen-binding fragment thereof.

[0024] In one embodiment of either aspect, the TACI binding domain comprises an anti-TACI single chain variable fragment (scFv).

[0025] In one embodiment of either aspect, the anti-TACI scFv comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1.

[0026] In one embodiment of either aspect, the VH comprises the amino acid sequence of SEQ ID NO:1.

[0027] In one embodiment of either aspect, the anti-TACI scFv comprises a light chain variable domain (VL) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2.

[0028] In one embodiment of either aspect, the VL comprises the amino acid sequence of SEQ ID NO:2.

[0029] In one embodiment of either aspect, the anti-TACI scFv comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2.

[0030] In one embodiment of either aspect, the VH is positioned N-terminal to the VL.

[0031] In one embodiment of either aspect, the VL is positioned N-terminal to the VH.

[0032] In one embodiment of either aspect, the VH and VL are linked via a linker sequence.

[0033] In one embodiment of either aspect, the linker sequence comprises the amino acid sequence of SEQ ID NO:3, 14, 15, 16, or 17.

[0034] In one embodiment of either aspect, the linker sequence comprises the amino acid sequence of SEQ ID NO:3.

[0035] In one embodiment of either aspect, the TACI binding domain comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:4 or 5.

[0036] In one embodiment of either aspect, the TACI binding domain comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0037] In one embodiment of either aspect, the transmembrane domain comprises a hinge / transmembrane domain.

[0038] In one embodiment of either aspect, the hinge / transmembrane domain comprises the hinge / transmembrane domain of an immunoglobulin-like protein, CD28, CD8, or 4-1BB.

[0039] In one embodiment of either aspect, the hinge / transmembrane domain is a CD8 hinge / transmembrane domain, and optionally, the CD8 hinge / transmembrane domain comprises the amino acid sequence of SEQ ID NO:7.

[0040] In one embodiment of any aspect, the intracellular signaling domain comprises an intracellular signaling domain of CD3ζ, CD3ε, or CD3θ.

[0041] In one embodiment of either aspect, the intracellular signaling domain comprises the intracellular signaling domain of CD3ζ, and optionally, the intracellular signaling domain of CD3ζ comprises the amino acid sequence of SEQ ID NO:9.

[0042] In one embodiment of any aspect, the costimulatory domain comprises a costimulatory domain of 4-1BB, CD28, CD27, ICOS, or OX40.

[0043] In one embodiment of either aspect, the costimulatory domain comprises a costimulatory domain of 4-1BB, and optionally, the costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO:8.

[0044] In one embodiment of either aspect, the CAR polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:10, 11, 12, or 13.

[0045] In one embodiment of either aspect, the extracellular target binding domain further comprises a target binding domain that binds to a second target that is not TACI.

[0046] In one embodiment of either aspect, the second target is B cell maturation antigen (BCMA).

[0047] In one embodiment of either aspect, the target binding domain comprises a ligand of a second target.

[0048] In one embodiment of either aspect, the target binding domain comprises an antibody or an antigen-binding fragment thereof.

[0049] In one embodiment of either aspect, the antibody or antigen-binding fragment thereof comprises an scFv.

[0050] In one embodiment of either aspect, the scFv is an anti-BCMA scFv.

[0051] In one embodiment of either aspect, the anti-BCMA scFv is located at the N-terminus of the anti-TACI scFv.

[0052] In one embodiment of either aspect, the anti-TACI scFv is located at the N-terminus of the anti-BCMA scFv.

[0053] In one embodiment of any aspect, the CAR polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs:18-25.

[0054] Another aspect of the present invention relates to a CAR polypeptide comprising the amino acid sequence of SEQ ID NO:10.

[0055] Another aspect of the present invention relates to a CAR polypeptide comprising the amino acid sequence of SEQ ID NO:11.

[0056] Another aspect of the present invention relates to a CAR polypeptide comprising the amino acid sequence of SEQ ID NO:12.

[0057] Another aspect of the present invention relates to a CAR polypeptide comprising the amino acid sequence of SEQ ID NO:13.

[0058] Another aspect of the invention described herein relates to a CAR polypeptide comprising the amino acid sequence of any one of SEQ ID NOs:18-25.

[0059] Another aspect of the invention described herein pertains to a polynucleotide encoding any one of the CAR polypeptides described herein.

[0060] In one embodiment, the polynucleotide further comprises a suicide gene.

[0061] In one embodiment, the polynucleotide further comprises a sequence encoding a signal sequence.

[0062] Another aspect of the invention described herein relates to a mammalian cell comprising any one of the CAR polypeptides described herein and / or any one of the polynucleotides described herein. In one embodiment, the mammalian cell is an induced pluripotent stem cell (iPSC). In one embodiment, the mammalian cell is an immune cell. In one embodiment, the immune cell is a T cell or a natural killer (NK) cell. In one embodiment, the mammalian cell is a human cell.

[0063] Another aspect of the invention described herein relates to a bispecific antibody that binds to TACI and CD3, the bispecific antibody comprising a TACI-binding domain and a CD3-binding domain.

[0064] In one embodiment of either aspect, the TACI binding domain has a K D In one embodiment, the TACI binding domain binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the TACI binding domain binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the TACI binding domain binds to TACI with a K of about 861 pM. D It binds to TACI.

[0065] In one embodiment of either aspect, the TACI binding domain comprises a VH comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:1, and / or a VL comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:2.

[0066] Another aspect of the invention described herein relates to a bispecific antibody that specifically binds to TACI and CD3, comprising a TACI binding domain and a CD3 binding domain, wherein the TACI binding domain comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2.

[0067] In one embodiment of either aspect, the TACI binding domain is located N-terminal to the CD3 binding domain.

[0068] In one embodiment of either aspect, the CD3 binding domain is located N-terminal to the TACI binding domain.

[0069] In one embodiment of either aspect, the TACI binding domain and the CD3 binding domain are linked by a linker sequence.

[0070] In one embodiment of either aspect, the linker sequence comprises the amino acid sequence of SEQ ID NO:3, 14, 15, 16, or 17.

[0071] In one embodiment of either aspect, the bispecific antibody is a monoclonal, human, humanized, or chimeric antibody.

[0072] In one embodiment of either aspect, the bispecific antibody is a monoclonal antibody.

[0073] In one embodiment of either aspect, the bispecific antibody is a full-length antibody.

[0074] In another embodiment of either aspect, the bispecific antibody is an antibody fragment that specifically binds to TACI and CD3, hi one embodiment, the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments.

[0075] In another embodiment of either aspect, the bispecific antibody is an IgG antibody. In one embodiment, the bispecific antibody is an IgG1 antibody.

[0076] Another aspect of the invention described herein pertains to a composition comprising any one of the bispecific antibodies described herein.

[0077] Another aspect of the invention described herein pertains to a polynucleotide encoding any one of the bispecific antibodies described herein.

[0078] Another aspect of the invention described herein pertains to a vector comprising any one of the polynucleotides encoding the bispecific antibodies described herein.

[0079] Another aspect of the invention described herein pertains to a host cell comprising any one of the vectors (e.g., a vector comprising any one of the polynucleotides encoding the bispecific antibodies described herein). In one embodiment, the host cell is a mammalian cell. In one embodiment, the mammalian cell is a Chinese Hamster Ovary (CHO) cell. In another embodiment, the host cell is a prokaryotic cell. In one embodiment, the prokaryotic cell is E. coli.

[0080] Another aspect of the invention described herein relates to a method for producing a bispecific antibody that specifically binds to TACI and CD3, the method comprising culturing any of the host cells described herein (e.g., a host cell comprising any of the vectors (e.g., a vector comprising any of the polynucleotides encoding the bispecific antibodies described herein)) in a culture medium.

[0081] In one embodiment, the method further comprises recovering the bispecific antibody from the host cell or culture medium.

[0082] Another aspect of the invention described herein relates to a method of treating a disease or disorder in a subject in need of treatment, comprising administering to the subject one or more of the following: (i) any one of the CAR polypeptides described herein, any one of the polynucleotides described herein, and / or any one of the mammalian cells described herein; (ii) any one of the antibodies described herein; (iii) any one of the antibody drug conjugates described herein; and (iv) any one of the bispecific antibodies described herein.

[0083] In one embodiment, the disease or disorder is cancer, an autoimmune disorder, or a plasma cell dyscrasia or disorder.

[0084] In one embodiment, the disease or disorder is cancer.

[0085] In one embodiment, the cancer comprises cells that express TACI.

[0086] In one embodiment, the cancer is multiple myeloma.

[0087] In one embodiment, the subject is refractory to anti-BCMA therapy.

[0088] In one embodiment, the disease or disorder is an autoimmune disease or disorder.

[0089] In one embodiment, the autoimmune disease or disorder is characterized by high titers of antibodies that contribute to the autoimmune disorder.

[0090] In one embodiment, the autoimmune disease or disorder is graft rejection, graft-versus-host disease, or hemophilia with factor inhibitors.

[0091] In one embodiment, the disease or disorder is a plasma cell dyscrasia or disorder.

[0092] In one embodiment, the plasma cell disease or disorder is plasma cell dysplasia, plasmacytoma, plasma cell leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, isolated plasmacytoma, extramedullary plasmacytoma, osteosclerosing myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

[0093] [Definition] For convenience, the meanings of some terms and phrases used in the specification, examples, and appended claims are provided below. Unless otherwise specified or implied from the context, the following terms and phrases have the meanings set forth below. The definitions are provided to help describe certain embodiments and are not intended to limit the claimed technology, since the scope is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this technology belongs. In the event of an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided in the specification shall prevail.

[0094] Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, Merck Sharp & Dohme Corp., 2011 (ISBN 978-0-911910-19-3); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, 2014 (ISBN 0815345305, 9780815345305);Lewin's Genes XI, Jones & Bartlett Publishers, 2014 (ISBN-1449659055);Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X);Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542);Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (ed.) John Wiley and Sons, Inc., 2003 (ISBN The company can be found at: 0471142735, 9780471142737.

[0095] In some embodiments, "activated" can refer to the state of a T cell that has been sufficiently stimulated to induce detectable cell proliferation. In some embodiments, activation can refer to induced cytokine production. In other embodiments, activation can refer to detectable effector function. As used herein, an "activated T cell" is at least a proliferating T cell.

[0096] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y is generally measured by the dissociation constant (K DAffinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.

[0097] As used herein, "administering" refers to a method of providing a dosage of a compound (e.g., an anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR) or composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition comprising an anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR) to a subject. The compositions utilized in the methods described herein can be administered or formulated for administration, for example, intramuscularly, intravenously, intradermally, transdermally, intra-arterially, intraperitoneally, intralesionally, intracranially, intra-articularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, subcutaneously, subconjunctivally, intravesically, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, injection, infusion, continuous infusion, directly by a localized perfusion bath target cell, by catheter, lavage, cream, or lipid composition. Methods of administration can vary depending on a variety of factors (e.g., the compound or composition being administered and the severity of the condition, disease, or disorder being treated). Preferably, a compound (e.g., an anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR of the invention) or composition (e.g., a pharmaceutical composition comprising an anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR) is administered or formulated for oral administration.

[0098] The terms "anti-TACI antibody," "antibody that binds to TACI," and "antibody that specifically binds to TACI" refer to an antibody that can bind to TACI with sufficient affinity such that the antibody is useful as a prophylactic, diagnostic, and / or therapeutic agent by targeting TACI. In one embodiment, the extent of binding of an anti-TACI antibody to an unrelated, non-TACI protein is less than about 10% of the binding of the antibody to TACI, e.g., as measured by radioimmunoassay (RIA). In certain embodiments, an antibody that binds to TACI has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 Dissociation constant (K D ).

[0099] The term "antibody" as used herein in its broadest sense encompasses various antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity. An "antibody" may refer, for example, to a glycoprotein comprising at least two heavy chains (HC) and two light chains (LC) interconnected by disulfide bonds, or an antigen-binding portion thereof. Each heavy chain is composed of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region may be composed of three domains, CH1, CH2, and / or CH3. Each light chain is composed of a light chain variable region (VL) and a light chain constant region (CL). The VH and VL regions can be further subdivided into hypervariable regions called "complementarity determining regions" (CDRs), interspersed with more conserved regions called "framework regions" (FRs). Each VH and VL may be composed of, for example, three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant region of the antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0100] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that specifically binds to an antigen (e.g., TACI) to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. These antibody fragments are obtained using conventional techniques, and the fragments are screened for utility in the same manner as intact antibodies. Antibody fragments can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact immunoglobulins.

[0101] "Bispecific T cell engager", "BiTE antibody construct" or "BiTE" refers to a polypeptide comprising single chain variable fragments (scFv) linked in tandem. Optionally, the scFvs are linked by a linker (e.g., a glycine-rich linker). One scFv of the BiTE binds to the T cell receptor (TCR) (e.g., CD3ε subunit) and the other binds to a target antigen (e.g., a tumor-associated antigen).

[0102] As used herein, the term "chimera" refers to a fusion product of portions of at least two or more different polynucleotide molecules. In one embodiment, the term "chimera" refers to a gene expression element produced through the manipulation of known elements or other polynucleotide molecules.

[0103] The term "chimeric antigen receptor" or "CAR" or "CARs" as used herein refers to an engineered T cell receptor that transfers ligand or antigen specificity to a T cell (e.g., naive T cell, central memory T cell, effector memory T cell, or a combination thereof). CAR is also known as an artificial T cell receptor, chimeric T cell receptor, or chimeric immune receptor. As used herein, "CAR T cell" or "CAR-T" refers to a T cell expressing a CAR. When expressed in a T cell, a CAR has the ability to redirect the specificity and reactivity of the T cell toward a selected target in an MHC-unrestricted manner, utilizing the antigen-binding properties of, for example, a monoclonal antibody. MHC-unrestricted antigen recognition provides the CAR-expressing T cell with the ability to recognize antigens independent of antigen processing, bypassing a major mechanism of tumor escape.

[0104] The term "costimulatory ligand" as used herein includes a molecule on an antigen presenting cell (APC) that specifically binds to a cognate co-stimulatory molecule on a T cell, thereby providing a signal that mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, etc., in addition to the primary signal provided by engagement of the TCR / CD3 complex with an MHC molecule, e.g., containing a peptide. Costimulatory ligands can include, but are not limited to, 4-1BBL, OX40L, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, inducible COStimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonists or antibodies that bind to Toll-like receptors, and ligands that specifically bind B7-H3. Costimulatory ligands may also include, but are not limited to, antibodies that specifically bind to costimulatory molecules present on T cells, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83. Other costimulatory ligands known in the art may also be used according to standard methods.

[0105] "Costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, Toll-like receptors, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83.

[0106] The terms "reduce", "reduced", "reduction" or "inhibit" refer to a decrease of at least 10% compared to a reference level (e.g., in the absence of a given treatment or agent), and may include, for example, a decrease of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or more. Typically, such a decrease is statistically significant. As used herein, "reduce" or "inhibit" does not encompass complete inhibition or reduction compared to a reference level. "Complete inhibition" is 100% inhibition compared to a reference level. Where applicable, the decrease may preferably be down to a level that is accepted as within the normal range for an individual without a given disorder.

[0107] A "disease" is a health condition of an animal, e.g., a human, in which the animal is unable to maintain homeostasis and the animal's health continues to deteriorate if the disease is not ameliorated. In contrast, an animal's "disorder" is a health condition in which the animal is able to maintain homeostasis, but the animal's health is less favorable than it would be in the absence of the disorder. If left untreated, the disorder does not necessarily cause the animal's health to further deteriorate.

[0108] The term "EC50" as used herein refers to the concentration of an antibody, or antigen-binding portion thereof, that induces a response that is 50% of the maximal response (i.e., halfway between the maximal response and the baseline) in either an in vivo or in vitro assay.

[0109] The terms "effective amount," "effective dose," and "effective dosage" as used herein are defined as an amount sufficient to achieve or at least partially achieve a desired effect. The term "therapeutically effective dose" or "therapeutically effective amount" is defined as an amount sufficient to prevent, cure, or at least partially halt a disease (e.g., diarrhea) and its complications in a patient already suffering from or at risk of developing the disease. Amounts effective for this use will depend on the severity of the disorder being treated and the general state of the patient's own immune system.

[0110] The term "modified" and its grammatical equivalents, as used herein, can refer in some embodiments to one or more human-designed changes in a nucleic acid, e.g., a nucleic acid in the genome of an organism. In other embodiments, modified can refer to a change, addition, and / or deletion of a gene. A "modified cell" can refer to a cell in which a gene has been added, deleted, and / or changed. As used herein, the terms "cell" or "modified cell" and their grammatical equivalents can refer to a cell of human or non-human animal origin.

[0111] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds. Epitopes can be formed from both contiguous or non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. Epitopes typically include at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial conformation. Methods for determining the spatial conformation of epitopes include those in the art and described herein, e.g., x-ray crystallography and two-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, edited by GE Morris (1996). Epitopes can also be defined by point mutations in the target protein (eg, TACI) that affect binding of an antibody (eg, a monoclonal antibody).

[0112] The terms "full length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain that includes an Fc region as defined herein.

[0113] The term "host cell" as used herein is intended to refer to a cell into which an expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but also to the progeny of such a cell. Because certain modifications may occur in successive generations, either due to mutation or environmental influences, such progeny may not actually be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

[0114] The term "human antibody" includes antibodies having variable and constant regions (if present) of human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) (see, e.g., Lonberg, N. et al. (1994) Nature 368(6474): 856-859; Lonberg, N. (1994) Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D. (1995) Intern. Rev. Immunol. Vol. 13: 65-93, and Harding, F. and Lonberg, N. (1995) Ann. NY Acad. Sci 764:536-546). However, the term "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences (i.e., humanized antibodies).

[0115] An "isolated antibody" is one that has been identified and separated and / or recovered from components of its natural environment and / or is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds TACI is substantially free of antibodies that specifically bind antigens other than TACI). Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody is (1) greater than 95% by weight, and most preferably greater than 99% by weight, of the antibody as determined by the Lowry method, (2) to the extent sufficient to obtain N-terminal or internal amino acid sequence of at least 15 residues using a spinning cup sequenator, or (3) to the extent sufficient to obtain N-terminal or internal amino acid sequence of at least 15 residues using a Coomassie TMIsolated antibodies are purified to homogeneity by SDS-PAGE under reducing or non-reducing conditions using either recombinant blue or, preferably, silver stain. Isolated antibodies include the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Similarly, isolated antibodies include the antibody in medium surrounding recombinant cells. Ordinarily, however, isolated antibodies will be prepared by at least one purification step.

[0116] The "K" used here D The term "antibody-antigen dissociation equilibrium constant" is intended to refer to the dissociation equilibrium constant of a particular antibody-antigen interaction. Typically, an antibody has a dissociation equilibrium constant of, for example, about 10, as determined by surface plasmon resonance (SPR) technology on a BIACORE3000 instrument using recombinant TACI as the analyte and the antibody as the ligand. -7 M, 10 -8 M, 10 -9 M or 10 -10 Less than M or even lower, about 10 -6 The dissociation equilibrium constant (K D ) binds to TACI.

[0117] The term "monoclonal antibody" as used herein refers to an antibody that displays a single binding specificity and affinity for a particular epitope. Thus, the term "human monoclonal antibody" or "HuMab" refers to an antibody that displays a single binding specificity and has variable and constant regions derived from human germline immunoglobulin sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma that includes B cells obtained from a transgenic non-human animal, e.g., a transgenic mouse, whose genome includes human heavy chain and light chain transgenes fused to an immortalized cell.

[0118] As used herein, the term "operably linked" refers to a first polynucleotide molecule, such as a promoter, linked to a second transcribable polynucleotide molecule, such as a gene of interest, where the polynucleotide molecules are arranged such that the first polynucleotide molecule affects the function of the second polynucleotide molecule. The two polynucleotide molecules may or may not be part of a single contiguous polynucleotide molecule, and may or may not be adjacent. For example, a promoter is operably linked to a gene of interest if the promoter regulates or mediates the transcription of the gene of interest in a cell.

[0119] In some embodiments, a polypeptide described herein (or a nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a "functional fragment" is a fragment or segment of a peptide that retains at least 50% of the activity of a wild-type reference polypeptide according to assays known in the art or described herein below. Functional fragments can include conservative substitutions of the sequences disclosed herein.

[0120] In some embodiments, the polypeptides described herein may be variants of the polypeptides or molecules described herein. In some embodiments, the variants are conservatively modified variants. Conservative substitution variants can be obtained, for example, by mutation of the native nucleotide sequence. A "variant" as referred to herein is a polypeptide that is substantially homologous to a native or reference polypeptide, but has an amino acid sequence that differs from that of the native or reference polypeptide due to one or more deletions, insertions, or substitutions. A DNA sequence encoding a variant polypeptide includes sequences encoding variant proteins or fragments thereof that contain one or more additions, deletions, or substitutions of nucleotides when compared to the native or reference DNA sequence, but that retain the activity of the non-variant polypeptide. A wide variety of PCR-based site-directed mutagenesis approaches are known in the art and can be applied by the skilled artisan. For example, a variant amino acid or DNA sequence can be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to a native or reference sequence.

[0121] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps as necessary to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for sequence alignment, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.

[0122] As used herein, the term "DNA" is defined as deoxyribonucleic acid. The term "polynucleotide" is used interchangeably herein with "nucleic acid" to refer to a polymer of nucleosides. Typically, polynucleotides are composed of nucleosides naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) linked by phosphodiester bonds. However, the term encompasses molecules containing nucleosides or nucleoside analogs, including chemically or biologically modified bases, modified backbones, and the like, whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. When this application refers to polynucleotides, it is understood that both DNA, RNA, and in each case single-stranded and double-stranded forms (and the complement of each single-stranded molecule) are provided. As used herein, "polynucleotide sequence" can refer to the polynucleotide material itself and / or the sequence information (i.e., the series of letters used as abbreviations for bases) that biochemically characterize a particular nucleic acid. Polynucleotide sequences presented herein are presented in the 5' to 3' orientation unless otherwise indicated.

[0123] The term "polypeptide" as used herein means a polymer of amino acids. The terms "protein" and "polypeptide" are used interchangeably herein. A peptide is a relatively short polypeptide, typically about 2 to 60 amino acids in length. A polypeptide as used herein typically contains amino acids, such as the 20 L-amino acids most commonly found in proteins. However, other amino acids and / or amino acid analogs known in the art can be used. One or more of the amino acids in a polypeptide can be modified, for example, by adding chemical entities such as carbohydrate groups, phosphate groups, fatty acid groups, linkers for conjugation, functional groups, etc. A polypeptide to which a non-polypeptide moiety is covalently or non-covalently attached is still considered a "polypeptide". Exemplary modifications include glycosylation and palmitoylation. A polypeptide can be purified from a natural source, produced using recombinant DNA technology, or synthesized by chemical means such as conventional solid-phase peptide synthesis. The terms "polypeptide sequence" or "amino acid sequence" as used herein can refer to the polypeptide material itself and / or to sequence information that biochemically characterizes the polypeptide (i.e., a series of letters or three-letter codes used as abbreviations for the names of amino acids). Polypeptide sequences presented herein are presented in an N-terminal to C-terminal orientation, unless otherwise indicated.

[0124] In some embodiments, a nucleic acid encoding a polypeptide (e.g., a CAR polypeptide) described herein is included in a vector, e.g., an expression vector. In some of the aspects described herein, a nucleic acid sequence encoding a given polypeptide described herein is operably linked to a vector. As used herein, the term "vector" refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral. The term "vector" encompasses any genetic element that can replicate when associated with the appropriate regulatory elements and transfer a genetic sequence to a cell. Vectors can include, but are not limited to, cloning vectors, expression vectors, plasmids, phages, transposons, cosmids, artificial chromosomes, viruses, virions, and the like.

[0125] As used herein, the term "expression vector" refers to a vector that directs the expression of an RNA or polypeptide from a sequence linked to a transcriptional regulatory sequence on the vector. The sequence to be expressed is often, but not necessarily, heterologous to the cell. An expression vector may contain additional elements, for example, an expression vector may have two replication systems, thereby allowing it to be maintained in two organisms, for example, for expression in human cells and for cloning and amplification in a prokaryotic host. The term "expression" refers to the intracellular processes involved in the production of RNA and proteins, and suitably the secretion of proteins, including, but not limited to, transcription, transcript processing, translation, and protein folding, modification, and processing, as applicable. An "expression product" includes RNA transcribed from a gene and a polypeptide obtained by translation of mRNA transcribed from a gene. The term "gene" refers to a nucleic acid sequence that is transcribed into RNA (DNA) in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as 5' untranslated (5'UTR) or "leader" sequences and 3'UTR or "trailer" sequences, as well as intervening sequences (introns) between individual coding segments (exons).

[0126] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin and is capable of being packaged into a viral vector particle. The viral vector may contain a nucleic acid encoding a polypeptide as described herein in place of non-essential viral genes. The vector and / or particle may be utilized for the purpose of transferring the nucleic acid into cells either in vitro or in vivo. Many forms of viral vectors are known in the art.

[0127] By "recombinant vector" is meant a vector that contains a heterologous nucleic acid sequence or "transgene" that can be expressed in vivo. It is understood that the vectors described herein can be combined with other suitable compositions and therapeutics in some embodiments. In some embodiments, the vector is episomal. The use of a suitable episomal vector provides a means to maintain a nucleotide of interest in a high copy number of extrachromosomal DNA in a subject, thereby eliminating the potential effects of chromosomal integration.

[0128] The term "pharmaceutical composition" refers to a preparation that is in a form that allows the biological activity of the active ingredients contained therein to be effective and that does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered.

[0129] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, additives, stabilizers, or preservatives.

[0130] As used herein, the terms "specific binding" and "specifically bind" refer to a physical interaction between two molecules, compounds, cells and / or particles in which a first entity binds to a second target entity with greater specificity and affinity than it binds to a third, non-target entity. In some embodiments, specific binding can refer to an affinity of a first entity for a second target entity that is at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, or more, greater than its affinity for a third, non-target entity under the same conditions. A reagent specific for a given target is one that exhibits specific binding to that target under the conditions of the assay being utilized. Non-limiting examples include antibodies or ligands that recognize and bind to cognate binding partner (e.g., stimulatory and / or costimulatory molecule) proteins present on T cells. For example, a specific antibody may have a specificity of, for example, about 10 times, as determined by surface plasmon resonance (SPR) techniques on a BIACORE3000 instrument using recombinant TACI as the analyte and an antibody as the ligand. -8 M, 10 -9 M or 10 -10 About 10, such as less than M -7 Affinity (K D ) to bind its target. In some embodiments, the binding of an antibody to a predetermined antigen is with an affinity that is at least two-fold greater than its binding affinity to a non-specific antigen other than the predetermined antigen (e.g., BSA, casein) or a closely related antigen. The phrases "antibody that recognizes an antigen" and "antibody specific for an antigen" are used interchangeably herein with the term "antibody that specifically binds to an antigen."

[0131] As used herein, "signal peptide" or "signal sequence" refers to a peptide at the N-terminus of a newly synthesized protein that serves to direct the nascent protein to the endoplasmic reticulum. In some embodiments, the signal peptide is the CD8 signal peptide.

[0132] As used herein, a "stimulatory ligand" refers to a ligand that, when present on an antigen-presenting cell (APC) (e.g., macrophage, dendritic cell, B cell, artificial APC, etc.), can specifically bind to a cognate binding partner (referred to herein as a "stimulatory molecule" or "costimulatory molecule") on a T cell, thereby mediating a primary response by the T cell, including, but not limited to, proliferation, activation, initiation of an immune response, etc. Stimulatory ligands are well known in the art and include, among others, peptide-containing MHC class I molecules, anti-CD3 antibodies, superagonist anti-CD28 antibodies, and superagonist anti-CD2 antibodies.

[0133] The term "stimulatory molecule" as used herein means a molecule on a T cell that specifically binds to a cognate stimulatory ligand present on an antigen-presenting cell.

[0134] A "subject" or "individual" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, deer, and rodents (e.g., mice and rats). In certain embodiments, the subject or individual is a human.

[0135] The subject may be one who has previously been diagnosed with or has been determined to be suffering from or having a condition in need of treatment (e.g., a disease or disorder described herein) or one or more complications associated with such a condition, and in some cases, has already been treated for the condition or one or more complications associated with the condition. Alternatively, the subject may also not have previously been diagnosed as having such a condition or associated complication. For example, the subject may be one who exhibits one or more risk factors for the condition or one or more complications associated with the condition, or one who does not exhibit risk factors.

[0136] A "subject in need" of treatment for a particular condition can be a subject who has the condition, has been diagnosed as having the condition, or is at risk for developing the condition.

[0137] The term "transmembrane activator and calcium modulator and cyclophilin ligand interactor" or "TACI", also known as tumor necrosis factor receptor (TNFR) superfamily member 13B (TNFRSF13B), is a lymphocyte-specific member of the TNFR superfamily. TACI interacts with two other members of the tumor necrosis factor (TNF) family, B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL), to regulate T cell-independent B cell antibody responses, isotype switching, and B cell homeostasis.

[0138] As used herein, the terms "treat", "treatment", "treating" or "amelioration" refer to therapeutic treatments whose purpose is to reverse, alleviate, ameliorate, inhibit, slow or stop the progression or severity of a condition associated with a disease or disorder, such as glioblastoma, glioma, acute lymphoblastic leukemia or other cancer, disease or disorder. The term "treating" includes reducing or alleviating at least one side effect or symptom of a condition, disease or disorder. Treatment is generally "effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is "effective" if the progression of the disease is reduced or stopped. That is, "treatment" includes not only improvement of symptoms or markers, but also a halt or at least slowing of the progression or worsening of symptoms compared to symptoms that would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptoms, reduction in the extent of the disease, stabilization of the disease state (i.e., not worsening), delay or slowing of disease progression, amelioration or palliation of the disease state, remission (partial or complete), and / or reduced mortality, whether detectable or undetectable. The term "treatment" of a disease also includes providing relief from the symptoms or side effects of the disease (including palliative treatment).

[0139] As used herein, the terms "tumor antigen" and "cancer antigen" are used interchangeably to mean antigens that are differentially expressed by cancer cells and therefore available for targeting cancer cells. Cancer antigens are antigens that can potentially stimulate apparently tumor-specific immune responses. Some of these antigens are encoded by normal cells, although not necessarily expressed. These antigens can be characterized as those that are normally silent (i.e., not expressed) in normal cells, those that are expressed only at certain stages of differentiation, and those that are transiently expressed, such as embryonic and fetal antigens. Other cancer antigens are encoded by mutated cellular genes, such as oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53), and fusion proteins resulting from internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes, such as those carried by RNA and DNA tumor viruses.

[0140] Other terms are defined within the description of various aspects and embodiments of the technology, as described below.

[0141] The constructs and methods described herein offer several advantages. For example, one advantage offered by the anti-TACI antibodies, antibody drug conjugates, BiTEs, and anti-TACI CARs described herein is that by targeting TACI, the problem of BCMA antigen escape can be mitigated. Although anti-BCMA therapy has previously shown promising results for multiple myeloma, targeting BCMA has also been shown to lead to relapse and / or BCMA antigen reduction after BCMA CAR T cell therapy. The frequency of this occurrence has yet to be determined, but a recent study observed an overall response rate of 85% but a median progression-free survival of 11.8 months (Raje et al., N Engl J Med. 2019;380(18):1726-1737), indicating that monospecific targeting of BCMA by CAR T cells may not be a curative treatment for most patients. Reports of disease resistance due to BCMA antigen reduction under the selective pressure of anti-BCMA CAR T cell therapy have also emerged. Targeting TACI therefore offers unique advantages in treating diseases affected by BCMA antigen escape.

[0142] The above summary is intended to illustrate in a non-limiting manner some of the embodiments, advantages, features, and applications of the technology disclosed herein. Other embodiments, advantages, features, and applications of the technology disclosed herein will become apparent from the detailed description, drawings, examples, and claims. [Brief description of the drawings]

[0143] The accompanying drawings are not intended to be drawn to scale. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. In the drawings: [Figure 1]FIG. 1 illustrates the general method used to generate transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) antibodies and their use in the anti-TACI chimeric antigen receptor (CAR) T cells described herein. [Diagram 2] FIG. 2 is a graph showing the results of a surface plasmon resonance assay using an anti-TACI antibody. [Diagram 3] FIG. 3 shows the design of the anti-TACI CARs referred to herein as "anti-TACI(H / L)" and "anti-TACI(L / H)." [Figure 4] FIG. 4 is a series of graphs showing BCMA and TACI expression in MM1S, MM1S BCMA knockout, K562, K562-TACI, and K562-BCMA cell lines. [Diagram 5] FIG. 5 is a series of graphs showing TACI expression in T cells. [Figure 6] Figure 6 is a graph showing transfection efficiency of anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells as measured by mCherry expression. Multiplicity of infection (MOI)=10. [Figure 7] Figure 7 is a graph showing the killing activity of untransduced (UTD), anti-BCMA, anti-TACI (H / L), and anti-TACI (L / H) CAR T cells using MM1S cells as target cells. [Figure 8] Figure 8 is a graph showing the killing activity of UTD, anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells using MM1S BCMA knockout cells as target cells. [Figure 9] 9 is a series of graphs showing CD45RO and CCR7 expression on T cells to determine the immunophenotype of T cells (e.g., naive T cells, central memory (CM) T cells, effector memory (EM) T cells, and late effector T cells (EMRA)). It is observed that the CM T cell population is enriched. [Figure 10] Figure 10 is a series of graphs showing CD95 and CD127 expression on the naive T cell populations (i.e., CD45-CCR7+ T cells) identified in Figure 9. CD95 and CD127 are biomarkers for T stem cell memory (TSCM) populations. [Figure 11] Figure 11 is a graph showing CD107a expression on anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells. CD107a is a marker of cytotoxic degranulation. [Figure 12A] Figures 12A-12C are a series of graphs showing binding of anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells to soluble TACI (sTACI) (Figure 12A), soluble BCMA (sBCMA) (Figure 12B), and soluble APRIL (sAPRIL) (Figure 12C). [Figure 12B] the above [Figure 12C] the above [Figure 13A] 13A-13E are a series of graphs showing cytokine production of anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells incubated with MM1S target cells (Figure 13A), MM1S BCMA knockout cells (Figure 13B), K562-BCMA cells (Figure 13C), K562-TACI cells (Figure 13D), and U266 cells (Figure 13E). [Figure 13B] the above [Figure 13C] the above [Figure 13D] the above [Figure 13E] the above [Figure 14] Figure 14 is a graph showing population doublings of anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells in response to stimulation with K562-expressing target cells. [Figure 15]Figure 15 shows the experimental design for testing UTD, anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells in vivo. Mice are injected intravenously (iv) with 1x106 MM1S cells. Two weeks later, mice are injected with 2x106 CAR T or UTD cells. Bioluminescence images are taken twice a week. [Figure 16A] 16A and 16B are images taken by bioluminescence imaging showing the tumor burden in mice. [Figure 16B] the above [Figure 17] FIG. 17 is a graph showing quantification of tumor burden in mice as measured by bioluminescence (photons / second). [Figure 18] Figure 18 is a graph showing tumor killing by UTD, anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells. [Figure 19] Figure 19 is a graph showing mouse survival after treatment with UTD, anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells. [Figure 20A] Figures 20A-20E show the function of anti-TACI CARs. Figure 20A shows the construct design of anti-TACI and control anti-BCMA CARs. [Figure 20B] FIG. 20B shows BCMA and TACI staining. [Figure 20C] Figure 20C shows luciferase-based killing assays of anti-TACI CAR and anti-BCMA CAR (control) against multiple myeloma cell lines MM1S, RPM1-8266, and U266. [Figure 20D] FIG. 20D shows in vivo luciferase imaging after CAR treatment of MM1S. [Figure 20E] Figure 20E shows binding of soluble TACI to BCMA and TACI CAR. [Figure 21A]Figures 21A-21E show a comparison of tandem bispecific BCMA-TACI CAR vs. TriPRIL. Figure 21A shows the design of the dual targeting CAR T cell construct. [Figure 21B] FIG. 21B shows the transduction efficiency of the constructs. [Figure 21C] Figure 21C shows luciferase-based killing assays of the dual-targeting CAR against multiple myeloma cell lines MM1S, RPM1-8226, and U266. [Figure 21D] Figure 21D shows expression of BCMA and TACI in MM1S cells expressing non-specific CRISPR / Cas9, BCMA-targeting CRISPR / Cas9, and TACI-targeting CRISPR / Cas9. [Figure 21E] FIG. 21E shows a luciferase-based killing assay for the MM1S knockout cell line from FIG. 21D in flat-bottom plates. [Figure 22A] Figures 22A-22C show luciferase-based killing assays using CARs targeting three different myeloma lines. T cells were incubated with tumor cell lines expressing CBG-GFP for 18 hours, then lysed and analyzed for luciferase expression. [Figure 22B] the above [Figure 22C] the above [Diagram 23] FIG. 23 shows staining of peripheral blood mononuclear cells (PBMCs) with TACI antibodies as measured by flow cytometry. [Figure 24] FIG. 24 shows transduction efficiency of normal donor T cells with anti-TACI HL, anti-TACI LH, or anti-BCMA as measured by % mCherry positive cells in flow cytometry analysis. [Figure 25A]Figures 25A-25B show measurements of soluble TACI protein binding to non-transduced T cells and T cells expressing anti-TACI HL, anti-TACI-H, or anti-BCMA. Cells were incubated with various concentrations of fluorescent soluble TACI protein, after which cellular fluorescence was measured using flow cytometry and expressed as the percentage of cells positive for TACI (Figure 25A) or median fluorescence intensity (MFI) relative to the signal measured in non-transduced cells (Figure 25B). [Figure 25B] the above [Figure 26A] Figures 26A-26H show the effect of CAR T cells on RPMI8226 subcutaneous tumors in mice. Figure 26A shows the experimental timeline. Figures 26B-26F show individual growth curves of RPMI8226 tumors in mice treated with anti-TACI HL CAR (Figure 26B), anti-TACI LH CAR (Figure 26C), anti-BCMA CAR (Figure 26D), or non-transduced T cells (Figure 26E, negative control), or left untreated (Figure 26F, negative control). Figure 26G shows mouse survival over time. Figure 26H shows the number of CAR T cells per microliter of mouse blood 21 days after intravenous administration of 2x106 CAR T cells. [Figure 26B] the above [Figure 26C] the above [Figure 26D] the above [Figure 26E] the above [Figure 26F] the above [Figure 26G] the above [Fig. 26H] the above [Figure 27A] Figures 27A-27B show that the effect of anti-TACI CAR T cells is specific to tumor cells expressing TACI. Figure 27A shows flow cytometry analysis of MM1S Cas9 cancer cells stained for TACI and BCMA with or without Cas9-disrupted TACI. [Figure 27B]Figure 27B shows the cytotoxicity of MM1S Cas9 and MM1S Cas9 TACI knockout resulting from co-incubation with anti-TACI HL CAR, anti-TACI LH CAR, anti-BCMA CAR, or non-transduced T cells at various ratios of T cells to cancer cells. [Figure 28] Figure 28 shows the binding affinity of bispecific and monospecific CAR T cells to their respective soluble antigens as measured by flow cytometry. The top two plots show the binding of fluorescent BCMA and the bottom two plots show the binding of fluorescent TACI to anti-TACI H-L CAR, anti-TACI L-H CAR, anti-BCMA, anti-TACI / anti-BCMA bispecific CAR, anti-BCMA / anti-TACI bispecific CAR, or non-transduced T cells. The left two plots show the percentage of cells positive for BCMA or TACI. The right two plots show the median fluorescence intensity of each cell population compared to non-transduced cells. [Figure 29] Figure 29 shows measurements of cytokine concentrations in supernatants from cultures of MM1S (top plot) or RPMI8226 (bottom plot) cancer cells alone or in co-culture with anti-TACI / anti-BCMA bispecific CARs, anti-BCMA / anti-TACI bispecific CARs, or non-transduced T cells. The left plot shows interleukin-2 (IL-2) concentrations, the middle plot shows interferon gamma (IFNg) concentrations, and the right plot shows tumor necrosis factor alpha (TNFa) concentrations. [Figure 30A]Figures 30A-30E show the results of the MM1S stress model with bispecific CAR T cells. Figure 30A shows the experimental timeline where mice were intravenously injected with 1x106 MM1S cells on day -14, followed by 2x106 CAR T cells on day 0, with bioluminescence imaging measurements on days 0, 4, 7, 11, and 14. Figures 30B, 30C, and 30D show the bioluminescence flux from MM1S cells measured in mice treated with T cells (transduced with anti-TACI / anti-BCMA bispecific CAR or anti-BCMA / anti-TACI bispecific CAR, or non-transduced) from three different donors, or left untreated. Figure 30E shows a representative bioluminescence image from a mouse treated with cells from donor 1. [Figure 30B] the above [Figure 30C] the above [Figure 30D] the above [Figure 30E] the above [Figure 31A] Figures 31A-31F show results from the RPMI8226 subcutaneous tumor model. Figure 31A shows the experimental timeline, where 5x106 RPMI8226 cells were implanted subcutaneously into mice on day -14, followed by 2x106 CAR T cells injected intravenously on day 0, and tumor caliper measurements were taken on days 0, 4, 7, 10, and 14. Figure 31B shows the number of CAR T cells per microliter in the blood of mice on day 14 (left) and day 21 (right). [Figure 31B] the above [Fig. 31C-31F] Figures 31C, 31D, 31E, and 31F show tumor volume curves measured in mice treated with anti-TACI / anti-BCMA bispecific CAR (Figure 31C), anti-BCMA / anti-TACI bispecific CAR (Figure 31D), or non-transduced (Figure 31E) T cells, or left untreated (Figure 31F). [Figure 32A]Figures 32A-32B show the results of an experiment monitoring T cell exhaustion after repeated antigen stimulation. Figure 32A shows the experimental timeline in which 1x106 T cells (untransduced or transduced with anti-BCMA CAR, anti-TACI / anti-BCMA bispecific CAR, or anti-BCMA / anti-TACI bispecific CAR) were stimulated with irradiated K562 cells overexpressing BCMA on day 0, and flow cytometry analysis was performed on days 0, 7, 14, 21, and 28 to monitor exhaustion and memory phenotype. T cells were counted at each time point, re-normalized to 1x106 cells, and restimulated. [Figure 32B] FIG. 32B shows the results of flow cytometry measurements of Tim-3 and Lag3 on T cells over time. [Figure 33A] Figures 33A-33C show the results of the analysis of T cell phenotype in repeatedly stimulated CAR T cells. Figure 33A shows the experimental timeline in which 1x106 CAR T cells were stimulated with irradiated K562 cells overexpressing BCMA on day 0, counted, and analyzed by flow cytometry on days 0, 7, 14, and 21. CAR T cells were restimulated on days 7 and 14. [Figure 33B] Figure 33B shows the percentage of each type of CAR T cell (anti-BCMA, anti-TACI / anti-BCMA bispecific, or anti-BCMA / anti-TACI bispecific) sorted by flow cytometry into each effector phenotype according to the definitions shown on the left (central memory (CM): CCR7+CD45RA-; effector memory (EM): CCR7-CD45RA-; naive: CCR7+CD45RA+; well-differentiated effector (TDE): CCR7-CD45RA+). [Figure 33C] Figure 33C shows the expansion of CAR T cells over time as cells / 106. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0144] Provided herein are anti-transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) antibodies, antibody-drug conjugates thereof, bispecific T cell engagers (BiTEs) targeting TACI, and anti-TACI chimeric antigen receptors (CARs). Such antibodies, antibody-drug conjugates, BiTEs, and CARs can be used, for example, in methods for treating cancer, autoimmune disorders, or plasma cell dyscrasias or disorders in a subject in need thereof.

[0145] [Anti-TACI antibody] The present invention provides an isolated antibody that specifically binds to TACI. The disclosure provides, in some embodiments, heavy and light chain variable domain sequences, and heavy and light chain CDR sequences of the anti-TACI antibodies described herein. When different definition systems (e.g., the IMGT definition, the Kabat definition, or the Chothia definition) are used, the CDRs of the antibodies may have different amino acid sequences. In one definition system, each amino acid in a given antibody sequence (e.g., the VH or VL sequence) is annotated, and the numbers corresponding to the heavy and light chain CDRs are provided in Table 3. Example CDR sequences of anti-TACI antibodies according to different definition systems are provided in Table 4.

[0146] In some embodiments, an anti-TACI antibody of the present disclosure comprises one or more of the CDR-H (e.g., CDR-H1, CDR-H2, and CDR-H3) amino acid sequences from any one of the anti-TACI antibodies selected from Table 4. In some embodiments, an anti-TACI antibody of the present disclosure comprises CDR-H1, CDR-H2, and CDR-H3 as provided for each numbering system provided in Table 4. In some embodiments, an anti-TACI antibody of the present disclosure comprises one or more of the CDR-L (e.g., CDR-L1, CDR-L2, and CDR-L3) amino acid sequences from any one of the anti-TACI antibodies selected from Table 4. In some embodiments, an anti-TACI antibody of the present disclosure comprises CDR-L1, CDR-L2, and CDR-L3 as provided for each numbering system provided in Table 4.

[0147] In some embodiments, an anti-TACI antibody of the disclosure comprises CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 as provided for each numbering system in Table 4. In some embodiments, the heavy and light chain CDR3 domains of an antibody may play a particularly important role in the binding specificity / affinity of the antibody to an antigen. Thus, an anti-TACI antibody of the disclosure may comprise at least the heavy and / or light chain CDR3 of any one of the anti-TACI antibodies provided in Table 4.

[0148] In some embodiments, an anti-TACI antibody of the disclosure comprises a heavy chain variable domain CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequence of SEQ ID NO: 1. Alternatively or additionally, an anti-TACI antibody of the disclosure comprises a light chain variable domain CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequence of SEQ ID NO:2.

[0149] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having the amino acid sequence of SEQ ID NO:26 (according to the IMGT definition system), a CDR-H2 having the amino acid sequence of SEQ ID NO:27 (according to the IMGT definition system), a CDR-H3 having the amino acid sequence of SEQ ID NO:28 (according to the IMGT definition system), a CDR-L1 having the amino acid sequence of SEQ ID NO:29 (according to the IMGT definition system), a CDR-L2 having the amino acid sequence of SEQ ID NO:30 (according to the IMGT definition system), and a CDR-L3 having the amino acid sequence of SEQ ID NO:31 (according to the IMGT definition system).

[0150] In some embodiments, an anti-TACI antibody of the disclosure includes CDR-H1, CDR-H2, and CDR-H3 that collectively include no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO:26, CDR-H2 having the amino acid sequence of SEQ ID NO:27, and CDR-H3 having the amino acid sequence of SEQ ID NO:28. "Collectively" means that the total number of amino acid mutations of all three heavy chain CDRs is within a defined range. Alternatively or in addition, an anti-TACI antibody of the disclosure includes CDR-L1, CDR-L2, and CDR-L3 that collectively include no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO:29, CDR-L2 having the amino acid sequence of SEQ ID NO:30, and CDR-L3 having the amino acid sequence of SEQ ID NO:31.

[0151] In some embodiments, an anti-TACI antibody of the disclosure comprises a CDR-H1, CDR-H2, and CDR-H3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-H1 having the amino acid sequence of SEQ ID NO:26, a CDR-H2 having the amino acid sequence of SEQ ID NO:27, and a CDR-H3 having the amino acid sequence of SEQ ID NO:28. Alternatively, or in addition, an anti-TACI antibody of the disclosure comprises a CDR-L1, CDR-L2, and CDR-L3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-L1 having the amino acid sequence of SEQ ID NO:29, a CDR-L2 having the amino acid sequence of SEQ ID NO:30, and a CDR-L3 having the amino acid sequence of SEQ ID NO:31.

[0152] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO:26; a CDR-H2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H2 having the amino acid sequence of SEQ ID NO:27; and / or a CDR-H3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H3 having the amino acid sequence of SEQ ID NO:28. Alternatively or in addition, the anti-TACI antibodies of the present disclosure include a CDR-L1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO:29; a CDR-L2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L2 having the amino acid sequence of SEQ ID NO:30; and / or a CDR-L3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L3 having the amino acid sequence of SEQ ID NO:31.

[0153] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having the amino acid sequence of SEQ ID NO: 32 (according to the Kabat definition system), a CDR-H2 having the amino acid sequence of SEQ ID NO: 33 (according to the Kabat definition system), a CDR-H3 having the amino acid sequence of SEQ ID NO: 34 (according to the Kabat definition system), a CDR-L1 having the amino acid sequence of SEQ ID NO: 35 (according to the Kabat definition system): a CDR-L2 having the amino acid sequence of SEQ ID NO: 36 (according to the Kabat definition system), and a CDR-L3 having the amino acid sequence of SEQ ID NO: 31 (according to the Kabat definition system).

[0154] In some embodiments, an anti-TACI antibody of the disclosure comprises CDR-H1, CDR-H2, and CDR-H3 that collectively comprise no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO: 32, CDR-H2 having the amino acid sequence of SEQ ID NO: 33, and CDR-H3 having the amino acid sequence of SEQ ID NO: 34. "Collectively" means that the total number of amino acid mutations of all three heavy chain CDRs is within a defined range. Alternatively or in addition, an anti-TACI antibody of the disclosure comprises CDR-L1, CDR-L2, and CDR-L3 that collectively comprise no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO: 35, CDR-L2 having the amino acid sequence of SEQ ID NO: 36, and CDR-L3 having the amino acid sequence of SEQ ID NO: 31.

[0155] In some embodiments, an anti-TACI antibody of the disclosure comprises a CDR-H1, CDR-H2, and CDR-H3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-H1 having the amino acid sequence of SEQ ID NO: 32, a CDR-H2 having the amino acid sequence of SEQ ID NO: 33, and a CDR-H3 having the amino acid sequence of SEQ ID NO: 34. Alternatively, or in addition, an anti-TACI antibody of the disclosure comprises a CDR-L1, CDR-L2, and CDR-L3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-L1 having the amino acid sequence of SEQ ID NO: 35, a CDR-L2 having the amino acid sequence of SEQ ID NO: 36, and a CDR-L3 having the amino acid sequence of SEQ ID NO: 31.

[0156] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO:32; a CDR-H2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H2 having the amino acid sequence of SEQ ID NO:33; and / or a CDR-H3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H3 having the amino acid sequence of SEQ ID NO:34. Alternatively or in addition, the anti-TACI antibodies of the present disclosure include a CDR-L1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO:35; a CDR-L2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L2 having the amino acid sequence of SEQ ID NO:36; and / or a CDR-L3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L3 having the amino acid sequence of SEQ ID NO:31.

[0157] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having the amino acid sequence of SEQ ID NO:37 (according to the Chothia defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO:38 (according to the Chothia defined system), a CDR-H3 having the amino acid sequence of SEQ ID NO:39 (according to the Chothia defined system), a CDR-L1 having the amino acid sequence of SEQ ID NO:40 (according to the Chothia defined system): a CDR-L2 having the amino acid sequence of SEQ ID NO:30 (according to the Chothia defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO:41 (according to the Chothia defined system).

[0158] In some embodiments, an anti-TACI antibody of the disclosure comprises CDR-H1, CDR-H2, and CDR-H3 that collectively comprise no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO: 37, CDR-H2 having the amino acid sequence of SEQ ID NO: 38, and CDR-H3 having the amino acid sequence of SEQ ID NO: 39. "Collectively" means that the total number of amino acid mutations of all three heavy chain CDRs is within a defined range. Alternatively or in addition, an anti-TACI antibody of the disclosure comprises CDR-L1, CDR-L2, and CDR-L3 that collectively comprise no more than 5 amino acid mutations (e.g., no more than 5, 4, 3, 2, or 1 amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO: 40, CDR-L2 having the amino acid sequence of SEQ ID NO: 30, and CDR-L3 having the amino acid sequence of SEQ ID NO: 41.

[0159] In some embodiments, an anti-TACI antibody of the disclosure comprises a CDR-H1, CDR-H2, and CDR-H3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-H1 having the amino acid sequence of SEQ ID NO: 37, a CDR-H2 having the amino acid sequence of SEQ ID NO: 38, and a CDR-H3 having the amino acid sequence of SEQ ID NO: 39. Alternatively, or in addition, an anti-TACI antibody of the disclosure comprises a CDR-L1, CDR-L2, and CDR-L3 that are collectively at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to a CDR-L1 having the amino acid sequence of SEQ ID NO: 40, a CDR-L2 having the amino acid sequence of SEQ ID NO: 30, and a CDR-L3 having the amino acid sequence of SEQ ID NO: 41.

[0160] In some embodiments, an anti-TACI antibody of the present disclosure comprises a CDR-H1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H1 having the amino acid sequence of SEQ ID NO:37; a CDR-H2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H2 having the amino acid sequence of SEQ ID NO:38; and / or a CDR-H3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-H3 having the amino acid sequence of SEQ ID NO:39. Alternatively or in addition, the anti-TACI antibodies of the present disclosure include a CDR-L1 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L1 having the amino acid sequence of SEQ ID NO:40; a CDR-L2 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L2 having the amino acid sequence of SEQ ID NO:30; and / or a CDR-L3 having three or fewer amino acid mutations (e.g., three, two, or one or fewer amino acid mutations) compared to CDR-L3 having the amino acid sequence of SEQ ID NO:41.

[0161] In some embodiments, an anti-TACI antibody of the disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 1. Alternatively, or in addition, an anti-TACI antibody of the disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO:2.

[0162] In some embodiments, an anti-TACI antibody of the disclosure comprises a VH that contains 20 or fewer amino acid changes (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid changes) when compared to the VH set forth in SEQ ID NO: 1. Alternatively or additionally, an anti-TACI antibody of the disclosure comprises a VL that contains 20 or fewer amino acid changes (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid changes) when compared to the VL set forth in SEQ ID NO:2.

[0163] In some embodiments, an anti-TACI antibody of the disclosure comprises a VH comprising an amino acid sequence at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the VH set forth in SEQ ID NO: 1. Alternatively, or in addition, an anti-TACI antibody of the disclosure comprises a VL comprising an amino acid sequence at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the VL set forth in SEQ ID NO:2.

[0164] In some embodiments, the anti-TACI antibody of the present disclosure is a humanized antibody. In some embodiments, the humanized anti-TACI antibody comprises a humanized VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO:26 (according to the IMGT-defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO:27 (according to the IMGT-defined system), a CDR-H3 having the amino acid sequence of SEQ ID NO:28 (according to the IMGT-defined system); and a humanized VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO:29 (according to the IMGT-defined system), a CDR-L2 having the amino acid sequence of SEQ ID NO:30 (according to the IMGT-defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO:31 (according to the IMGT-defined system).

[0165] In some embodiments, the humanized anti-TACI antibody comprises a humanized VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO: 32 (according to the Kabat defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO: 33 (according to the Kabat defined system), a CDR-H3 having the amino acid sequence of SEQ ID NO: 34 (according to the Kabat defined system); and a humanized VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO: 35 (according to the Kabat defined system), a CDR-L2 having the amino acid sequence of SEQ ID NO: 36 (according to the Kabat defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO: 31 (according to the Kabat defined system).

[0166] In some embodiments, the humanized anti-TACI antibody comprises a humanized VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO: 37 (according to the Chothia defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO: 38 (according to the Chothia defined system), a CDR-H3 having the amino acid sequence of SEQ ID NO: 39 (according to the Chothia defined system); and a humanized VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO: 40 (according to the Chothia defined system), a CDR-L2 having the amino acid sequence of SEQ ID NO: 30 (according to the Chothia defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO: 41 (according to the Chothia defined system).

[0167] In some embodiments, the anti-TACI antibody is an IgG, a Fab fragment, a F(ab') fragment, a F(ab')2 fragment, an scFv, or an scFv fused to a constant region (e.g., an N- or C-terminal fusion). Non-limiting examples of different types of anti-TACI antibodies are provided herein.

[0168] In some embodiments, the anti-TACI antibody is a single chain variable fragment (scFv) comprising a VH and a VL on a single polypeptide chain. In some embodiments, the scFv comprises any one of the heavy chain CDRs, light chain CDRs, VH, and / or VL described herein on a single polypeptide chain. In some embodiments, the scFv comprises a VH linked at the N-terminus of the VL. In some embodiments, the scFv comprises a VL linked at the N-terminus of the VH. In some embodiments, the VH and VL are linked via a linker (e.g., a polypeptide linker). Any polypeptide linker can be used to link the VH and VL in the scFv. The selection of the linker sequence is within the skill of one of ordinary skill in the art.

[0169] In some embodiments, the scFv comprises a VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO:26 (according to the IMGT-defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO:27 (according to the IMGT-defined system), a CDR-H3 having the amino acid sequence of SEQ ID NO:28 (according to the IMGT-defined system); and a VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO:29 (according to the IMGT-defined system), a CDR-L2 having the amino acid sequence of SEQ ID NO:30 (according to the IMGT-defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO:31 (according to the IMGT-defined system), wherein the VH and VL are on a single polypeptide chain (e.g., linked via an amide bond or linked via a linker, such as a peptide linker), and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3). In some embodiments, the scFv comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0170] In some embodiments, the scFv comprises a VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO: 32 (according to the Kabat definition system), a CDR-H2 having the amino acid sequence of SEQ ID NO: 33 (according to the Kabat definition system), a CDR-H3 having the amino acid sequence of SEQ ID NO: 34 (according to the Kabat definition system); and a VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO: 35 (according to the Kabat definition system), a CDR-L2 having the amino acid sequence of SEQ ID NO: 36 (according to the Kabat definition system), and a CDR-L3 having the amino acid sequence of SEQ ID NO: 31 (according to the Kabat definition system), wherein the VH and VL are on a single polypeptide chain (e.g., linked via an amide bond or linked via a linker, such as a peptide linker), and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 3). In some embodiments, the scFv comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0171] In some embodiments, the scFv comprises a VH comprising a CDR-H1 having the amino acid sequence of SEQ ID NO: 37 (according to the Chothia defined system), a CDR-H2 having the amino acid sequence of SEQ ID NO: 38 (according to the Chothia defined system), a CDR-H3 (according to the Chothia defined system) having the amino acid sequence of SEQ ID NO: 39 (according to the Chothia defined system); and a VL comprising a CDR-L1 having the amino acid sequence of SEQ ID NO: 40 (according to the Chothia defined system), a CDR-L2 having the amino acid sequence of SEQ ID NO: 30 (according to the Chothia defined system), and a CDR-L3 having the amino acid sequence of SEQ ID NO: 41 (according to the Chothia defined system), wherein the VH and VL are on a single polypeptide chain (e.g., linked via an amide bond or linked via a linker, such as a peptide linker), and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3). In some embodiments, the scFv comprises the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0172] In some embodiments, the scFV comprises a VH comprising an amino acid sequence at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the VH set forth in SEQ ID NO:1, and a VL (e.g., a humanized VL) comprising an amino acid sequence at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the VL set forth in SEQ ID NO:2, where the VH and VL are in a single polypeptide chain (e.g., linked via an amide bond or linked via a linker, such as a peptide linker), and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3). In some embodiments, the scFv comprises an amino acid sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0173] In some embodiments, the scFV comprises a VH that contains no more than 20 amino acid mutations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations) compared to the VH set forth in SEQ ID NO:1, and a VL that contains no more than 20 amino acid mutations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations) compared to the VL set forth in SEQ ID NO:2, wherein the VH and VL are in a single polypeptide chain (e.g., linked via amide bonds or linked via a linker, such as a peptide linker), and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3). In some embodiments, the scFV comprises an amino acid sequence that contains 20 or fewer amino acid mutations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations) compared to the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:5.

[0174] In some embodiments, the scFV comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2, where the VH and VL are in a single polypeptide chain (e.g., linked via an amide bond or linked via a linker, such as a peptide linker) and the VH is linked to the N-terminus or C-terminus of the VL. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3).

[0175] In some embodiments, the scFv comprises a VH comprising the amino acid sequence of SEQ ID NO:1 linked to the N-terminus of a VL comprising the amino acid sequence of SEQ ID NO:2. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3).

[0176] In some embodiments, the scFv comprises a VH comprising the amino acid sequence of SEQ ID NO:1 linked to the C-terminus of a VL comprising the amino acid sequence of SEQ ID NO:2. In some embodiments, the VH and VL are linked via a linker comprising the amino acid sequence of GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3).

[0177] In some cases, the antibody has a K of about 5 nM or less (e.g., about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 900 pM or less, about 875 pM or less, about 850 pM or less, about 825 pM or less, about 800 pM or less, about 700 pM or less, about 600 pM or less, or about 500 pM or less). D In one embodiment, the antibody binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the antibody binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the antibody binds to TACI with a KD of about 861 pM.

[0178] In some cases, the antibody comprises a heavy chain variable domain (VH) sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having, SEQ ID NO: 1. In a further example, the antibody comprises a light chain variable domain (VL) sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having, SEQ ID NO:2. In some cases, the antibody comprises a VH sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of, SEQ ID NO:1, and a VL sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of SEQ ID NO:2.

[0179] Such antibodies may be, for example, monoclonal, human, humanized, or chimeric. The antibody may be a full-length antibody or an antibody fragment thereof (e.g., an antibody fragment that binds to TACI). The antibody fragment may be selected from the group consisting of Fab, Fab'-SH, Fv, scFv, and (Fab')2 fragments. In some cases, the antibody is an IgG antibody (e.g., an IgG1 antibody). Such antibodies may have a half-life of ≧3 days (e.g., ≧1 week, such as ≧2 weeks, such as ≧1 month, such as ≧2 months, such as ≧3 months, such as ≧4 months, such as ≧5 months, such as ≧6 months).

[0180] In further aspects, an anti-TACI antibody according to any of the above embodiments can include any of the features, either alone or in combination, as described in the following sections.

[0181] [Antibody affinity] In certain embodiments, the antibodies provided herein have a dissociation constant (K D In some cases, the antibody may have a K of about 5 nM or less (e.g., about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 900 pM or less, about 875 pM or less, about 850 pM or less, about 825 pM or less, about 800 pM or less, about 700 pM or less, about 600 pM or less, or about 500 pM or less). D In one embodiment, the antibody binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the antibody binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the antibody binds to TACI with a KD of about 861 pM.

[0182] In one embodiment, K D is measured by radiolabeled antigen binding assay (RIA). In one embodiment, an RIA is performed using the Fab form of the antibody of interest and its antigen. For example, the solution binding affinity of the Fab for the antigen is determined by the lowest concentration ( 125 I) is measured by equilibrating Fab with labeled antigen and then capturing bound antigen on anti-Fab antibody-coated plates (see, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish assay conditions, MICROTITER® multi-well plates (Thermo Scientific) were coated overnight with 5 μg / ml capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), followed by blocking with 2% (w / v) bovine serum albumin in PBS for 2 to 5 hours at room temperature (approximately 23° C.). In non-adsorbent plates (Nunc#269620), 100 pM or 26 pM [ 125I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of an anti-VEGF antibody, Fab-12, Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, incubation may be continued for a longer period (e.g., about 65 hours) to ensure equilibrium is reached. The mixture is then transferred to a capture plate for incubation (e.g., 1 hour) at room temperature. The solution is then removed and the plate is washed 8 times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. Once the plate has dried, 150 μl / well of scintillant (MICROSCINT-20®) is added. TM Packard) was added and the plate was counted using TOPCOUNT TM Count for 10 minutes in a gamma counter (Packard). Concentrations of each Fab that give 20% or less of maximal binding are selected for use in competitive binding assays.

[0183] According to another embodiment, K D is measured using a BIACORE® surface plasmon resonance assay. For example, the assay using a BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) is performed at 25° C. with immobilized antigen CM5 chips at approximately 10 response units (RU). In one embodiment, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate, pH 4.8, and then injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of bound protein. Following antigen injection, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) were incubated with 0.05% polysorbate 20 (TWEEN-20) at 25°C at a flow rate of approximately 25 μl / min. TM) in PBS containing surfactant (PBST). The binding rate (k on ) and dissociation rate (k off ) is calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the binding and dissociation sensorgrams. D ) to compare k on / k off See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate is 10 6 M -1 s -1 If the on speed exceeds 8000 series SLM-AMINCO with a stirred cuvette TM It can be determined using a fluorescence quenching technique (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) measuring the increase or decrease in fluorescence emission intensity of 20 nM anti-antigen antibody (Fab type) in PBS, pH 7.2 at 25°C in the presence of increasing concentrations of antigen, as measured with a spectrometer such as a spectrophotometer (ThermoSpectronic) or a spectrophotometer equipped with a stopped-flow (Aviv Instruments).

[0184] According to another embodiment, K D is measured using a surface plasmon resonance assay as described in Example 1 herein.

[0185] [Antibody fragment] In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, as known in the art. Also included are diabodies, which have two antigen binding sites, which may be bivalent or bispecific, as known in the art. Triabodies and tetrabodies are also known. Single domain antibodies are also antibody fragments that contain all or a portion of the heavy chain variable domain, or all or a portion of the light chain variable domain of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody.

[0186] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phages), as described herein.

[0187] [Chimeric and humanized antibodies] In certain embodiments, the antibodies provided herein are chimeric antibodies. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or a non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

[0188] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. In general, a humanized antibody comprises one or more variable domains in which the HVRs, e.g., CDRs (or portions thereof), are derived from a non-human antibody and the FRs (or portions thereof) are derived from a human antibody sequence. A humanized antibody optionally also comprises at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are replaced with the corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.

[0189] Human framework regions that may be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from consensus sequences of human antibodies of particular subgroups of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening of FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996).

[0190] [Human antibody] In certain embodiments, the antibodies provided herein are human antibodies (e.g., human monoclonal antibodies (HuMabs), e.g., anti-TACI HuMabs). Human antibodies can be produced using a variety of techniques known in the art.

[0191] Human monoclonal antibodies can be produced using a variety of known techniques, such as the standard somatic cell hybridization technique described in Kohler and Milstein, Nature 256:495 (1975). Although somatic cell hybridization procedures are preferred, in principle other techniques for producing monoclonal antibodies can be employed, such as viral or oncogenic transformation of B lymphocytes, phage display techniques using libraries of human antibody genes.

[0192] In some cases, human antibodies are obtained by cloning heavy and light chain genes directly from human B cells obtained from a human subject. B cells are isolated from peripheral blood (e.g., by flow cytometry, e.g., FACS), stained for B cell markers, and assessed for antigen binding. RNA encoding the heavy and light chain variable regions (or entire heavy and light chains) is extracted and reverse transcribed into DNA, from which the antibody genes are amplified (e.g., by PCR) and sequenced. The known antibody sequences can then be used to express recombinant human antibodies against a known target antigen (e.g., TACI).

[0193] In some cases, human antibodies can be prepared by administering an immunogen (e.g., TACI) to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigen challenge. Such animals typically contain all or part of a human immunoglobulin locus that replaces an endogenous immunoglobulin locus or is present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin locus is generally inactivated. The human variable regions from the intact antibodies produced by such animals can be further modified, for example, by combining with a different human constant region.

[0194] In some cases, human antibodies can also be produced by hybridoma-based methods. The preferred animal system for producing hybridomas that produce human monoclonal antibodies is the mouse system. Hybridoma production in mice, including immunization protocols and techniques for isolating and fusing immunized splenocytes, is well known in the art. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described.

[0195] Human antibodies can also be made by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.

[0196] Anti-TACI antibodies can also be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, an isolated nucleic acid is provided that encodes an anti-TACI antibody described herein. Such a nucleic acid can encode an amino acid sequence comprising the VL and / or an amino acid sequence comprising the VH of the antibody (e.g., the light and / or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such a nucleic acid are provided. In a further embodiment, a host cell comprising such a nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., is transformed with) (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g., a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). In one embodiment, a method for producing an anti-TACI antibody is provided, the method comprising culturing a host cell containing an antibody-encoding nucleic acid, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0197] For recombinant production of an anti-TACI antibody, nucleic acid encoding the antibody is isolated and inserted into one or more vectors for further cloning and / or expression in a host cell, e.g., as described above. Such nucleic acid can be readily isolated and sequenced using standard procedures (e.g., by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the antibody).

[0198] Suitable host cells for cloning or expressing antibody-encoding vectors include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be produced in bacteria, particularly if glycosylation and Fc effector functions are not required. After expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and further purified.

[0199] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast, including fungal or yeast strains whose glycosylation pathways have been "humanized," are suitable cloning or expression hosts for antibody-encoding vectors, resulting in the production of antibodies with partially or fully human glycosylation patterns.

[0200] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plants and insect cells. Many baculovirus strains have been identified that can be used in combination with insect cells, particularly for transfection of Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts.

[0201] Vertebrate cells may also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include SV40 transformed monkey kidney CV1 line (COS-7); human embryonic kidney lines (e.g., 293 or 293 cells described in Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumor (MMT060562); e.g., Mather et al., Annals NY Acad. Sci. 383:44-68 (1982); MRC5 cells; and FS4 cells. Other useful mammalian host cell lines include DHFR - These include Chinese Hamster Ovary (CHO) cells, including CHO cells, and myeloma cell lines, such as Y0, NS0, and Sp2 / 0.

[0202] [Antibody variants] In certain embodiments, amino acid sequence variants of anti-TACI antibodies are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of antibodies can be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions, and / or insertions and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions and substitutions can be made to arrive at the final construct, provided that the final construct has the desired characteristics, e.g., antigen binding.

[0203] In certain embodiments, antibody variants are provided that have one or more amino acid substitutions. Sites of interest for substitutional mutagenesis include the CDRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions." More substantial changes are provided in Table 1 under the heading of "exemplary substitutions" and are further described below with respect to amino acid side chain classes. Amino acid substitutions can be introduced into the antibody of interest and the products screened for the desired activity, e.g., retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC. JPEG0007584453000001.jpg183133

[0204] Amino acids can be grouped according to common side chain properties: (1) Hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) Acidic: Asp, Glu; (4) Basic: His, Lys, Arg; (5) Residues influencing chain orientation: Gly, Pro; (6) Aromatic: Trp, Tyr, Phe. Non-conservative substitutions involve exchanging a member of one of these classes for another class.

[0205] One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Generally, the resulting variant selected for further study has an altered (e.g., improved) biological property relative to the parent antibody (e.g., increased affinity, reduced immunogenicity) and / or substantially retains the biological property of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated using, for example, phage display-based affinity maturation techniques, such as those described herein. Briefly, one or more CDR residues are mutated and the variant antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).

[0206] Modifications (e.g., substitutions) can be made in the CDRs, for example, to improve antibody affinity. Such modifications can be made in "hot spots" of the CDRs, i.e., residues encoded by codons that undergo frequent mutation during the somatic maturation process, and / or residues that contact the antigen, and the resulting variants VH or VL are tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries is known in the art. In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then generated. The library is then screened to identify antibody variants with the desired affinity. Another method of introducing diversity involves a CDR-directed approach in which several CDR residues (e.g., 4-6 residues at a time) are randomized. CDR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.

[0207] In certain embodiments, substitutions, insertions, or deletions may be made within one or more CDRs, so long as such modifications do not substantially reduce the ability of the antibody to bind to the antigen. For example, conservative modifications (e.g., conservative substitutions provided herein) that do not substantially reduce binding affinity may be made within a CDR. Such modifications may, for example, be made outside of antigen contact residues within the CDR. In certain embodiments of the variant VH and VL sequences provided above, each CDR is unaltered or contains only one, two, or three amino acid substitutions.

[0208] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is called "alanine scanning mutagenesis" as described in Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a target residue or group (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) is identified and substituted with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether antigen-antibody interactions are affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to the initial substitution. Alternatively or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact and adjacent residues can be targeted as substitution candidates or can be eliminated. The variants can be screened to determine whether they contain the desired properties.

[0209] Amino acid sequence insertions include amino- and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g., for ADEPT) or a polypeptide which extends the serum half-life of the antibody.

[0210] In certain embodiments, modifications may be made to the Fc region of the antibody. These modifications may be made alone or in addition to modifications to one or more antibody variable domains (i.e., VH or VL regions) or regions thereof (e.g., one or more CDRs or FRs). Modifications to the Fc region may result in improved antibody effector function (e.g., complement-dependent cytotoxicity (CDC)), for example, by increasing C1q binding to opsonized cells. Exemplary mutations that improve CDC include, for example, Fc mutations E345R, E430G, and S440Y. Thus, an anti-TACI antibody may contain one or more CDC-enhancing Fc mutations that promote IgG hexamer formation and subsequent recruitment and activation of C1, the first component of complement.

[0211] In certain embodiments, modification of the amino acid sequence of the Fc region of an antibody can alter the half-life of the antibody in a host. Certain mutations that alter binding to the neonatal Fc receptor (FcRn) can extend the half-life of the antibody in serum. For example, an antibody with a tyrosine at heavy chain position 252, a threonine at heavy chain position 254, and a glutamic acid at heavy chain position 256 can have a dramatically extended serum half-life (see, e.g., U.S. Pat. No. 7,083,784).

[0212] [Characteristics of monoclonal antibodies against TACI] The sequence information of the human monoclonal antibodies of the present invention can be confirmed using sequencing techniques well known in the art. Similarly, the affinity of antibodies to TACI can also be assessed using standard techniques. For example, the affinity of HuMabs to TACI can be determined using Biacore3000. HuMabs are captured on the surface of a Biacore chip (GE healthcare) via, for example, amine coupling (sensor chip CM5). The captured HuMabs can be exposed to TACI in solution at various concentrations, and the affinity (K D )K on and K off can be calculated, for example, by BIAevaluation software.

[0213] The human monoclonal antibodies of the present invention can also be characterized for binding to TACI using various known techniques, such as ELISA, Western blot, etc. Generally, the antibodies are first characterized by ELISA. Optionally, an ELISA assay can be used to screen for antibodies and thus hybridomas that produce antibodies that show positive reactivity with the TACI immunogen. Hybridomas that bind TACI, preferably with high affinity, can then be subcloned and further characterized. One clone from each hybridoma that retains the reactivity of the parent cell (by ELISA) can then be selected for cell banking and antibody purification.

[0214] In some cases, a competition assay can be used to identify antibodies that compete with an anti-TACI antibody of the invention for binding to TACI. In certain embodiments, such competing antibodies bind to the same epitope (e.g., a linear or conformational epitope) bound by an anti-TACI antibody of the invention. Detailed exemplary methods for mapping the epitope to which an antibody binds are provided in Morris (1996) "Epitope Mapping Protocols," Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).

[0215] [Antibody-drug conjugates] In some embodiments, the anti-TACI antibodies of the present invention can be covalently attached to a drug moiety by a biodegradable stable linker (e.g., by a disulfide or non-cleavable thioether linker), i.e., as an antibody-drug conjugate. The drug to which the antibody is covalently attached can have a cytotoxic or cytostatic effect when not conjugated to the antibody. To achieve higher selectivity, and thus a lower effective dose, antibody-drug conjugates can be used to selectively deliver an effective dose of a cytotoxic drug to cells expressing TACI (e.g., tumor tissue expressing TACI). By achieving higher selectivity, the use of antibody-drug conjugates can also reduce systemic exposure and increase the tolerability of the drug. In addition, antibody-drug conjugates can improve the bioavailability of the drug and / or antibody compared to when the drug and / or antibody are administered in their unconjugated form.

[0216] [Bispecific T cell engager (BiTE)] Also provided herein are bispecific antibodies known as bispecific T cell engagers (BiTEs). Such molecules can target T cells by binding to a T cell antigen (e.g., by binding to CD3) as well as by binding to a target antigen, e.g., TACI. BiTEs can be used, for example, to enhance T cell responses in the tumor microenvironment. The two components of the BiTEs can be optionally separated from each other by a linker (e.g., a glycine / serine-based linker) as described herein and can be linked in either orientation, e.g., the anti-CD3 component to the N-terminus of the anti-TACI component, or vice versa.

[0217] Exemplary BiTEs useful in the methods described herein include a CD3 binding domain and a TACI binding domain. Such BiTEs can include an anti-CD3 scFv as the CD3 binding domain. The anti-CD3 scFv can be derived from any anti-CD3 antibody known in the art.

[0218] In some cases, the TACI binding domain (e.g., an antibody) has a K of about 5 nM or less (e.g., about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 900 pM or less, about 875 pM or less, about 850 pM or less, about 825 pM or less, about 800 pM or less, about 700 pM or less, about 600 pM or less, or about 500 pM or less). D In one embodiment, the TACI binding domain (e.g., an antibody) binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the TACI binding domain (e.g., an antibody) binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the TACI binding domain (e.g., an antibody) binds to TACI with a K of about 861 pM. D It binds to TACI.

[0219] Additionally, a BiTE can comprise a TACI binding domain derived from an anti-TACI antibody, as described above. In some embodiments, the TACI binding domain comprises a VH having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or a sequence of, SEQ ID NO:1. In a further embodiment, the TACI binding domain comprises a VL sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO:2, or the sequence thereof. In certain embodiments, the TACI binding domain comprises a VH sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of, SEQ ID NO:1, and a VL sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of, SEQ ID NO:2.

[0220] The TACI binding domain can be positioned N-terminal to the CD3 binding domain, or the CD3 binding domain can be positioned N-terminal to the TACI binding domain. The TACI binding domain and the CD3 binding domain can optionally be linked via a linker sequence, e.g., the linker sequences of SEQ ID NOs:3, 14, 15, 16, or 17 (described below), as well as any other linker described herein or known in the art.

[0221] [Chimeric Antigen Receptor (CAR)] The technology described herein provides improved chimeric antigen receptors (CARs) for use in immunotherapy. Next, various improvements to the CARs are discussed.

[0222] CAR refers to an engineered T cell receptor that transfers ligand or antigen specificity to a cell (e.g., a T cell, a natural killer (NK) cell, or an induced pluripotent stem cell (iPSC)) engineered to express the CAR. A CAR places a chimeric extracellular target binding domain that specifically binds to a target, e.g., a polypeptide, expressed on the surface of a cell targeted for a T cell response on a construct that includes a transmembrane domain and an intracellular domain of a T cell receptor molecule. In one embodiment, the chimeric extracellular target binding domain comprises an antigen binding domain of an antibody that specifically binds to an antigen expressed on a cell targeted for a T cell response. While the properties of the intracellular signaling domain of a CAR can vary as known in the art and disclosed herein, the chimeric target / antigen binding domain renders the receptor susceptible to signaling activation when the chimeric target / antigen binding domain binds to a target / antigen on the surface of a target cell.

[0223] With respect to intracellular signaling domains, so-called "first generation" CARs include those that provide only a CD3 zeta (CD3ζ) signal upon antigen binding. So-called "second generation" CARs include those that provide both a costimulatory (e.g., CD28 or CD137) and activation (CD3ζ) domain, and so-called "third generation" CARs include those that provide multiple costimulatory (e.g., CD28 and CD137) domains and an activation domain (e.g., CD3ζ). In various embodiments, the CAR is selected to have high affinity or avidity for the target / antigen - for example, target or antigen binding domains derived from antibodies generally have higher affinity and / or avidity for target antigens than naturally occurring T cell receptors. This property, combined with the high specificity that can be selected for antibodies, provides highly specific T cell targeting by CAR T cells.

[0224] [Extracellular target binding domain] As used herein, the term "extracellular target binding domain" refers to a polypeptide found outside of a cell sufficient to facilitate binding to a target. An extracellular target binding domain specifically binds to its binding partner, i.e., a target. As non-limiting examples, an extracellular target binding domain may include an antigen binding domain of an antibody or antibody reagent, or a ligand that recognizes and binds to a cognate binding partner protein. In this context, a ligand is a molecule that specifically binds to a portion of a protein and / or receptor. The cognate binding partner of a ligand useful in the methods and compositions described herein may generally be found on the surface of a cell. Ligand:cognate partner binding may result in a change in the receptor bearing the ligand or may activate a physiological response, e.g., activate a signal transduction pathway. In one embodiment, the ligand may be non-native to the genome. In some cases, the ligand has a function that is conserved across at least two species.

[0225] [Antibody Reagents] In various embodiments, the CARs described herein comprise an antibody reagent or an antigen-binding domain thereof as the extracellular target binding domain.

[0226] As used herein, the term "antibody reagent" refers to a polypeptide that comprises at least one immunoglobulin variable domain or immunoglobulin variable domain sequence and specifically binds to a given antigen. For example, antibody reagents useful for the CARs described herein include any one of the antibodies described above. An antibody reagent can comprise an antibody or a polypeptide comprising an antigen-binding domain of an antibody. In some embodiments of any of the aspects, an antibody reagent can comprise a monoclonal antibody or a polypeptide comprising an antigen-binding domain of a monoclonal antibody. For example, an antibody can comprise a VH and a VL. In another example, an antibody comprises two VHs and two VLs. The term "antibody reagent" encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv, CDR, and domain antibody (dAb) fragments (see, e.g., de Wildt et al., Eur. J. Immunol. 26(3):629-639, 1996, which is incorporated herein by reference in its entirety)) as well as complete antibodies. Antibodies may have the structural characteristics of IgA, IgG, IgE, IgD, or IgM (as well as combinations of subtypes thereof). Antibodies may be from any source, including mouse, rabbit, pig, rat, and primate (human and non-human primates) and primatized antibodies. Antibodies also include midibodies, humanized antibodies, chimeric antibodies, and the like. Completely human antibody binding domains may be selected, for example, from phage display libraries using methods known to those of skill in the art. Additionally, antibody reagents include single domain antibodies, such as camelid antibodies.

[0227] In one embodiment, the extracellular target binding domain of the CAR comprises or consists essentially of a single chain Fv (scFv) fragment, which is generated by fusing the VH and VL domains of an antibody, typically a monoclonal antibody, via a flexible linker peptide. In various embodiments, the scFv is fused to a transmembrane domain and a T cell receptor intracellular signaling domain, e.g., an engineered intracellular signaling domain as described herein. In another embodiment, the extracellular target binding domain of the CAR comprises a single domain (e.g., camelid) antibody. Antibody binding domains and methods for selecting and cloning them are well known to those of skill in the art.

[0228] [Target / antigen] Any cell surface moiety can be targeted by CAR. Often the target is a cell surface polypeptide that can be differentially or preferentially expressed on cells that one wishes to target for a T cell response. To target tumor or cancer cells, an antibody domain can be targeted, for example, to TACI, as described herein. Targeting tumor-specific or tumor-associated antigens can provide a means of targeting tumor cells while avoiding or at least limiting collateral damage to non-tumor cells or tissues.

[0229] The CAR provided herein targets TACI, a receptor that recognizes APRIL, BAFF, and CAML. TACI sequences are known in many species, such as human TACI (NCBI gene number: 23495) polypeptide (e.g., NCBI Reference Sequence: NP_036584.1) and mRNA (e.g., NCBI Reference Sequence: NM_012452.2). TACI may refer to human TACI, including naturally occurring variants, molecules, and alleles thereof. Homologs and / or orthologs of human TACI are easily identified for a given species by those skilled in the art, for example, using the NCBI ortholog search function or searching available sequence data for such species for sequences similar to the reference TACI sequence.

[0230] In certain instances, the CARs described herein can also target additional secondary targets, such as tumor antigens, tumor associated antigens, or other antigens of interest, including, but not limited to, BCMA, CD19, CD37, CEA, immature laminin receptor, TAG-72, HPV These include E6 and E7, BING-4, calcium activated chloride channel 2, cyclin B1, 9D7, Ep-CAM, EphA3, Her2 / neu, telomerase, mesothelin, SAP-1, survivin, BAGE family, CAGE family, GAGE ​​family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PRAME, SSX-2, Melan-A / MART-1, gp100 / pmel17, tyrosinase, TRP-1 / -2, MC1R, BRCA1 / 2, CDK4, MART-2, p53, Ras, MUC1, TGF-βRII, IL-15, IL13Ra2, and CSF1R. In certain embodiments, the second target is BCMA.

[0231] [TACI binding domain] In some embodiments, the invention provides an anti-TACI CAR comprising a TACI binding domain comprising an antibody reagent. In some cases, the TACI binding domain has a K of about 5 nM or less (e.g., about 5 nM or less, about 4 nM or less, about 3 nM or less, about 2 nM or less, about 1 nM or less, about 900 pM or less, about 875 pM or less, about 850 pM or less, about 825 pM or less, about 800 pM or less, about 700 pM or less, about 600 pM or less, or about 500 pM or less). D In one embodiment, the TACI binding domain binds to TACI with a K between about 500 pM and about 1 nM. D In one embodiment, the TACI binding domain binds to TACI with a K between about 700 pM and about 900 pM. D In one embodiment, the TACI binding domain binds to TACI with a K of about 861 pM. D It binds to TACI.

[0232] For example, the antibody reagent can be an anti-TACI antibody or antigen-binding fragment thereof, e.g., an anti-TACI scFv. In some embodiments, the anti-TACI scFv comprises a VH sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of SEQ ID NO:1. In other embodiments, the anti-TACI scFv comprises a VL sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO:2, or a sequence thereof. In some cases, the anti-TACI scFv comprises a VH sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of, SEQ ID NO:1, and a VL sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or having the sequence of SEQ ID NO:2. The VH can be positioned N-terminal to the VL (VH-VL), or the VL can be positioned N-terminal to the VH (VL-VH).

[0233] The VH and VL domains may be linked via a linker sequence. For example, linker sequences useful in the present invention include, but are not limited to, glycine / serine linkers such as GGGSGGGSGGGS (SEQ ID NO:14) and Gly4Ser(G4S) linkers such as (G4S)3(GGGGSGGGGSGGGGS (SEQ ID NO:15)) and (G4S)4(GGGGSGGGGSGGGGSGGGGS (SEQ ID NO:3)); the linker sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO:16) described in Whitlow et al., Protein Eng. 6(8):989-95, 1993, the contents of which are incorporated herein by reference in their entirety; Examples of linker sequences that can be used include the linker sequence GGSSRSSSSGGGGSGGGG (SEQ ID NO: 17), described in Sblattero et al., Nat. Biotechnol. 18(1):75-80, 2000, the contents of which are incorporated herein by reference in their entirety; and linker sequences with added functionality, such as coding sequences containing Cre-Lox recombination sites or epitope tags, described in Sblattero et al., Nat. Biotechnol. 18(1):75-80, 2000, the contents of which are incorporated herein by reference in their entirety.

[0234] In certain embodiments, the anti-TACI CAR described herein may comprise an anti-TACI scFv having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to SEQ ID NO:3 (VH-VL) or 4 (VL-VH), or a sequence thereof.

[0235] [Bispecific CAR] In another embodiment, a CAR useful in the technology described herein comprises at least two antigen-specific targeting regions, a transmembrane domain, and an extracellular target binding domain comprising an intracellular signaling domain. In such an embodiment, the two or more antigen-specific targeting regions target at least two different antigens and may be arranged in tandem and separated by a linker sequence. In another embodiment, the CAR is a bispecific CAR. A bispecific CAR is specific for two different antigens, e.g., TACI and any one of the additional targets described herein (e.g., BCMA).

[0236] For example, a bispecific CAR may target TACI and BCMA and comprise a TACI binding domain and a BCMA binding domain. Such a bispecific CAR may comprise a TACI binding domain (e.g., an anti-TACI scFv), as described above. In some embodiments, the BCMA binding domain comprises an anti-BCMA scFv. The anti-BCMA scFv may be derived from any anti-BCMA antibody known in the art. The TACI binding domain may be located N-terminal to the BCMA binding domain, or the BCMA binding domain may be located N-terminal to the TACI binding domain. The TACI binding domain and the BCMA binding domain may optionally be linked via a linker sequence, e.g., the linker sequences of SEQ ID NOs: 3, 14, 15, 16, or 17, as well as any other linkers described herein or known in the art.

[0237] In some embodiments, the TACI and BCMA targeting bispecific CARs described herein comprise an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of any one of SEQ ID NOs: 18-25. In some embodiments, the TACI and BCMA targeting bispecific CARs described herein comprise an amino acid sequence that is 80%, 85%, 90%, 95%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 18-25. In some embodiments, the TACI and BCMA targeting bispecific CARs described herein comprise an amino acid sequence of any one of SEQ ID NOs: 18-25.

[0238] [Hinge and transmembrane domains] Each CAR described herein comprises a transmembrane domain, e.g., a hinge / transmembrane domain, that connects the extracellular target binding domain to the intracellular signaling domain.

[0239] The binding domain of a CAR is optionally followed by one or more "hinge domains," which serve to position the antigen binding domain away from the effector cell surface to allow for proper cell / cell contact, antigen binding, and activation. A CAR optionally comprises one or more hinge domains between the binding domain and the transmembrane domain (TM). The hinge domain may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. The hinge domain may comprise the amino acid sequence of a naturally occurring immunoglobulin hinge region or a modified immunoglobulin hinge region. Exemplary hinge domains suitable for use in the CARs described herein include hinge regions derived from the extracellular regions of type 1 membrane proteins such as CD8 (e.g., CD8α), CD4, CD28, 4-1BB, and CD7, which may be wild-type hinge regions from these molecules or may be modified. In some embodiments, the hinge region is derived from the hinge region of an immunoglobulin-like protein (e.g., IgA, IgD, IgE, IgG, or IgM), CD28, or CD8. In one embodiment, the hinge domain comprises a CD8α hinge region.

[0240] As used herein, a "transmembrane domain" (TM domain) refers to a portion of a CAR that fuses the extracellular binding portion, optionally via a hinge domain, to the intracellular portion (e.g., the costimulatory domain and the intracellular signaling domain), anchoring the CAR to the cell membrane of an immune effector cell. A transmembrane domain is a generally hydrophobic region of a CAR that passes through the cell membrane of a cell. A TM domain can be a transmembrane region or fragment thereof of a transmembrane protein (e.g., a type I transmembrane protein or other transmembrane protein), an artificial hydrophobic sequence, or a combination thereof. Although specific examples are provided herein and used in the examples, other transmembrane domains will be apparent to those of skill in the art and can be used in connection with alternative embodiments of the technology. It is preferred that the selected transmembrane region or fragment thereof does not interfere with the intended function of the CAR. When used in connection with a transmembrane domain of a protein or polypeptide, a "fragment thereof" refers to a portion of the transmembrane domain sufficient to anchor or attach the protein to the cell surface.

[0241] In some examples, the transmembrane domain of a CAR described herein, or a fragment thereof, may be selected from the group consisting of the alpha, beta, or zeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), 4-1BBL, GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (K LRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7Ra, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT and / or NKG2C.

[0242] As used herein, "hinge / transmembrane domain" refers to a domain that includes both the hinge domain and the transmembrane domain. For example, the hinge / transmembrane domain can be derived from the hinge / transmembrane domain of CD8, CD28, CD7, or 4-1BB. In one embodiment, the hinge / transmembrane domain of the CAR or a fragment thereof is derived from or includes the hinge / transmembrane domain of CD8.

[0243] CD8 is an antigen found preferentially on the cell surface of cytotoxic T lymphocytes. CD8 mediates cell-cell interactions within the immune system and acts as a co-receptor for T cells. CD8 consists of alpha (CD8α or CD8a) and beta (CD8β or CD8b) chains. CD8a sequences are known for many species, for example, human CD8a (NCBI gene number: 925) polypeptide (e.g., NCBI Reference Sequence NP_001139345.1) and mRNA (e.g., NCBI Reference Sequence NM_000002.12). CD8 can refer to human CD8, including naturally occurring variants, molecules, and alleles thereof. In some embodiments of any of the aspects, for example, in veterinary applications, CD8 can refer to CD8, for example, canine, feline, bovine, equine, porcine, etc. Homologs and / or orthologs of human CD8 are readily identified for a species by one of skill in the art using, for example, the NCBI ortholog search function, or by searching available sequence data for a given species for sequences similar to the reference CD8 sequence.

[0244] In some embodiments, the CD8 hinge and transmembrane sequence corresponds to the amino acid sequence of SEQ ID NO:7; or comprises the sequence of SEQ ID NO:7; or comprises a sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO:7.

[0245] [Costimulatory domain] Each CAR described herein optionally comprises an intracellular domain or costimulatory domain of one or more costimulatory molecules. As used herein, the term "costimulatory domain" refers to the intracellular signaling domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or an Fc receptor that, upon binding to an antigen, provides a second signal required for efficient activation and function of T lymphocytes. The costimulatory domain can be, for example, the costimulatory domain of 4-1BB, CD27, CD28, or OX40. Additional illustrative examples of such costimulatory molecules include CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2C SLP76, TRIM, and ZAP70.

[0246] In one embodiment, the costimulatory domain is the costimulatory domain of 4-1BB. 4-1BB is a membrane receptor protein also known as CD137, a member of the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is expressed in activated T lymphocytes. 4-1BB sequences are known for many species, e.g., human 4-1BB, also known as TNFRSF9 (NCBI gene number: 3604) and mRNA (NCBI reference sequence: NM_001561.5). 4-1BB can refer to human 4-1BB, including naturally occurring variants, molecules, and alleles thereof. In some embodiments of any of the aspects, e.g., in veterinary applications, 4-1BB can refer to, e.g., canine, feline, bovine, equine, porcine, etc. 4-1BB. Homologs and / or orthologs of human 4-1BB are readily identified for a given species by one of skill in the art using, for example, the NCBI ortholog search function or by searching available sequence data for such species for sequences similar to the reference 4-1BB sequence.

[0247] In some embodiments, the costimulatory domain of 4-1BB corresponds to the amino acid sequence of SEQ ID NO:8; or comprises the sequence of SEQ ID NO:8; or comprises amino acids having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO:8.

[0248] [Intracellular signaling domain] The CARs described herein include an intracellular signaling domain. "Intracellular signaling domain" refers to the portion of a CAR polypeptide that is involved in transmitting the message of effective CAR binding to a target antigen to the interior of an immune effector cell to induce effector cell functions, such as activation, cytokine production, proliferation, and cytotoxic activity, including the release of cytotoxic factors to a target cell to which the CAR is bound, or other cellular responses elicited after antigen binding to the extracellular CAR domain. In various examples, the intracellular signaling domain is derived from CD3zeta (see, e.g., below). Further non-limiting examples of intracellular signaling domains that contain immunoreceptor tyrosine-based activation motifs (ITAMs) that are particularly useful in the art include those derived from TCRzeta, FcRgamma, FcRbeta, CD3gamma, CD3theta, CD3delta, CD3eta, CD3epsilon, CD3zeta, CD22, CD79a, CD79b, and CD66d.

[0249] CD3 is a T cell coreceptor that promotes T lymphocyte activation when engaged simultaneously with appropriate costimulation (e.g., binding of costimulatory molecules). The CD3 complex consists of four different chains; mammalian CD3 consists of the CD3γ chain, the CD3δ chain, and two CD3ε chains. These chains associate with a molecule known as the T cell receptor (TCR) and CD3ζ to generate an activation signal in the T lymphocyte. The complete TCR complex includes the TCR, CD3ζ, and the complete CD3 complex.

[0250] In some embodiments of any of the aspects, the CAR polypeptide described herein comprises an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif or ITAM from CD3 zeta (CD3ζ), including variants of CD3ζ, such as, for example, ITAM-mutated CD3ζ, CD3η, or CD3θ. In some embodiments of any of the aspects, the ITAM comprises an ITAM triad of CD3ζ (ITAM3). In some embodiments of any of the aspects, the ITAM triad of CD3ζ is not mutated and thus comprises a native or wild-type sequence. In some embodiments, the CD3ζ sequence comprises a CD3ζ sequence set forth in the sequences provided herein, e.g., SEQ ID NO:9, or a variant thereof.

[0251] For example, a CAR polypeptide described herein comprises an intracellular signaling domain of CD3zeta. In one embodiment, the CD3zeta intracellular signaling domain corresponds to or comprises the amino acid sequence of SEQ ID NO:9; or comprises the sequence of SEQ ID NO:9; or comprises amino acids having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO:9.

[0252] The individual CAR and other construct components described herein can be used in conjunction with one another and substituted in the various constructs described herein, as can be determined by one of skill in the art. Each of these components can comprise or consist of any of the corresponding sequences described herein, or variants thereof.

[0253] A more detailed description of CARs and CAR T cells can be found in Maus et al., Blood 123:2624-2635, 2014; Reardon et al., Neuro-Oncology 16:1441-1458, 2014; Hoyos et al., Haematologica 97:1622, 2012; Byrd et al., J. Clin. Oncol. 32:3039-3047, 2014; Maher et al., Cancer Res 69:4559-4562, 2009; and Tamada et al., Clin. Cancer Res. 18:6436-6445, 2012; each of which is incorporated herein by reference in its entirety.

[0254] In some embodiments, the CAR polypeptides described herein include a signal peptide. The signal peptide can be from any protein that has an extracellular domain or is secreted. The CAR polypeptides described herein can include any signal peptide known in the art. In some embodiments, the CAR polypeptides include a CD8 signal peptide, e.g., a CD8 signal peptide, including an amino acid sequence that corresponds to or includes the amino acid sequence of SEQ ID NO:6, or has at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) with the sequence of SEQ ID NO:6.

[0255] In further embodiments, the CAR polypeptides described herein can optionally exclude one of the signal peptides described herein, such as the CD8 signal peptide of SEQ ID NO:6.

[0256] In one embodiment, the CAR further comprises a linker domain. As used herein, "linker domain" refers to an oligo- or polypeptide region of about 2 to 100 amino acids in length that connects any of the domains / regions of the CAR described herein to one another. In some embodiments, the linker may comprise or consist of flexible residues such as glycine and serine, allowing adjacent protein domains to move freely relative to one another. Linker sequences useful in the present invention may be 2 to 100 amino acids in length, 5 to 50 amino acids in length, 10 to 15 amino acids in length, 15 to 20 amino acids in length, or 18 to 20 amino acids in length, and include any suitable linker known in the art and / or described herein (e.g., linker sequences of SEQ ID NOs: 3, 14, 15, 16, or 7). Longer linkers may be used when it is desired to prevent two adjacent domains from sterically interfering with one another. Additionally, the linker may be cleavable or non-cleavable. Examples of cleavable linkers include 2A linkers (e.g., P2A and T2A), 2A-like linkers or functional equivalents thereof and combinations thereof. In various examples, linkers having sequences described herein or variants thereof are used. It should be understood that the display of a particular linker in a construct at a particular position does not mean that only that linker can be used therein. Rather, different linker sequences (e.g., P2A and T2A) can be interchanged (e.g., in the context of the constructs of the invention) as can be determined by one of skill in the art. In one embodiment, the linker region is T2A from Thosea asigna virus. Non-limiting examples of linkers that can be used in this technology include T2A, P2A, E2A, BmCPV2A, and BmIFV2A.

[0257] In some embodiments, the CARs described herein optionally further comprise a reporter molecule, for example to allow for non-invasive imaging (e.g., positron emission tomography PET scans). In bispecific CARs that include a reporter molecule, the first extracellular binding domain and the second extracellular binding domain can include different or the same reporter molecule. In bispecific CAR T cells, the first CAR and the second CAR can express different or the same reporter molecule. In another embodiment, the CARs described herein can be expressed alone or in combination with a substrate or chemical (e.g., 9-[4-[ 18 F]fluoro-3]-(hydroxymethyl)butyl]guanine ([ 18 In another embodiment, the CAR described herein further comprises a reporter molecule (e.g., hygromycin phosphotransferase (hph)) that can be imaged in combination with a non-invasive technique (e.g., 64 Cu 2+ Further included are nanoparticles that can be easily imaged using gold nanoparticles (GNPs) functionalized with . Labeling of CAR T cells for non-invasive imaging is reviewed, for example, in Bhatnagar et al., Integr. Biol. (Camb). 5(1):231-238, 2013, and Keu et al., Sci. Transl. Med. 18; 9(373), 2017, which are incorporated herein by reference in their entireties.

[0258] GFP and mCherry are demonstrated herein as useful fluorescent tags for imaging CARs expressed on T cells (e.g., CAR T cells). It is expected that essentially any fluorescent protein known in the art can be used as a fluorescent tag for this purpose. For clinical applications, it is not necessary for the CAR to include a fluorescent tag or fluorescent protein. Thus, in each of the examples of specific constructs provided herein, any markers present in the construct can be removed. The present invention includes constructs with or without markers. Thus, when a specific construct is referred to herein, it can be considered to be included in the present invention regardless of the presence or absence of a marker or tag.

[0259] In some embodiments, the CAR polypeptide sequence corresponds to, includes, or comprises a sequence having at least 80% sequence identity (e.g., at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to the sequence of SEQ ID NO: 10, 11, 12, or 13, optionally excluding the CD8 signal peptide described herein. As can be determined by one of skill in the art, various functionally similar or equivalent components of these CARs can be exchanged or substituted for each other, as well as other similar or functionally equivalent components known in the art or listed herein.

[0260] [Nucleic acid encoding CAR] In some embodiments, any of the CAR polypeptides described herein (e.g., a CAR polypeptide of SEQ ID NO: 10, 11, 12, or 13) is encoded by a polynucleotide contained in a viral vector. In some cases, a polynucleotide encoding a CAR polypeptide described herein can be codon optimized to enhance expression or stability. Codon optimization can be performed according to any standard method known in the art. In some embodiments, expression of the CAR can be driven by a constitutively expressed promoter (e.g., the EF1α promoter) or an inducibly expressed promoter (e.g., an NFAT response element).

[0261] Furthermore, the polynucleotide of the present invention may include the expression of a suicide gene. This may be done to facilitate external drug-mediated control of the administered cells. For example, the suicide gene may be used to deplete the modified cells from the patient, for example, in the case of an adverse event. In one example, the FK506 binding domain is fused to the caspase 9 pro-apoptotic molecule. The T cells modified in this way are made sensitive to the immunosuppressant drug tacrolimus. Other examples of suicide genes are thymidine kinase (TK), CD20, thymidylate kinase, truncated prostate specific membrane antigen (PSMA), truncated low affinity nerve growth factor receptor (LNGFR), truncated CD19, and modified Fas, which may be triggered by conditional ablation by administering specific molecules (e.g., ganciclovir for TK+ cells) or antibodies or antibody drug conjugates.

[0262] Retroviruses, such as lentiviruses, provide a convenient platform for delivery of nucleic acid sequences encoding genes of interest or chimeric genes. A selected nucleic acid sequence can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells, for example, in vitro or ex vivo. Retroviral systems are well known in the art and are described, for example, in U.S. Pat. No. 5,219,740; Kurth and Bannert (2010) "Retroviruses: Molecular Biology, Genomics and Pathogenesis" Calster Academic Press (ISBN:978-1-90455-55-4); and Hu and Pathak Pharmacological Reviews 2000 52:493-512, which are incorporated herein by reference in their entirety. A lentiviral system for efficient DNA delivery can be purchased from OriGene (Rockville, MD). In alternative embodiments, a CAR polypeptide of any of the CARs described herein is expressed in a mammalian cell via transfection or electroporation of an expression vector containing a nucleic acid encoding the CAR. Transfection and electroporation methods are known in the art.

[0263] Efficient expression of any of the CAR polypeptides described herein can be assayed using standard assays to detect the mRNA, DNA, or gene product of the nucleic acid encoding the CAR, such as RT-PCR, FACS, Northern blotting, Western blotting, ELISA, or immunohistochemistry. In some embodiments, the CAR polypeptide of any of the CAR polypeptides described herein is encoded by a recombinant nucleic acid sequence.

[0264] [cell] Another aspect of the invention relates to a mammalian cell comprising any of the CAR polypeptides described herein; or a nucleic acid encoding any of the CAR polypeptides described herein. In one embodiment, the mammalian cell comprises an antibody, an antibody reagent, an antigen-binding portion thereof, or any of the CAR polypeptides described herein, or a nucleic acid encoding such an antibody, an antibody reagent, an antigen-binding portion thereof, or any of the CAR polypeptides described herein. The mammalian cell or tissue can be of human, primate, hamster, rabbit, rodent, bovine, porcine, ovine, equine, caprine, canine, or feline origin, although any other mammalian cell may be used. In a preferred embodiment of either aspect, the mammalian cell is human.

[0265] In one example, the mammalian cell is an induced pluripotent stem cell (iPSC), e.g., as described in Takahashi K and Yamanaka S, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell. 126(4):663-76 (2006), which is incorporated herein by reference in its entirety. In other embodiments, the cell is an immune cell. As used herein, "immune cell" refers to a cell that plays a role in an immune response. Immune cells are of hematopoietic origin and include lymphocytes, e.g., B cells and T cells; natural killer cells; myeloid cells, e.g., monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes. In some embodiments, the immune cells are T cells; NK cells; NKT cells; lymphocytes, e.g., B cells and T cells; and myeloid cells, e.g., monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes. In one embodiment, the cell is a T cell or a natural killer (NK) cell.

[0266] The mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells)) can be obtained from a subject who has or has been diagnosed with cancer, a plasma cell disease or disorder, or an autoimmune disease or disorder. For example, the mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells)) can be obtained from a subject who has cancer, e.g., multiple myeloma, smoldering myeloma, or Waldenstrom's macroglobulinemia. In some embodiments, the mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells)) are obtained from a subject who is resistant to anti-BCMA therapy. The cells can also be obtained from an allogeneic donor who is a non-genetically identical individual of the same species as the intended recipient of the cells.

[0267] Mammalian cells (e.g., iPSCs or immune cells (e.g., T or NK cells)) that can be used in the present invention include autologous cells obtained from the subject to whom the cells are subsequently administered after ex vivo modification and expansion. For example, mammalian cells (e.g., iPSCs or immune cells (e.g., T or NK cells)) can be obtained from an individual who has or has been diagnosed with cancer, a plasma cell disease or disorder, or an autoimmune disease or disorder. Mammalian cells (e.g., iPSCs or immune cells (e.g., T or NK cells)) can also be obtained from an allogeneic donor who is a non-genetically identical individual of the same species as the intended recipient of the cells. Mammalian cells useful in the present invention include, but are not limited to, iPSCs and immune cells (e.g., T or NK cells).

[0268] Methods for obtaining T cells and NK cells are known in the art and may be useful for the modified immune cells described herein. T cells and NK cells are typically obtained from peripheral blood, which is collected from a subject, for example, by venipuncture or withdrawal through an implanted port or catheter. In some cases, blood can be obtained by a process involving leukapheresis, in which leukapheresis cells are obtained from the subject's blood and other blood components are returned to the subject. Blood or leukapheresis products (fresh or frozen) are processed to enrich for T cells or NK cells using methods known in the art. For example, density gradient centrifugation (e.g., using Ficoll) and / or counter-flow centrifugal elutriation can be performed to enrich for mononuclear cells (including T cells or NK cells). In one example, in the case of T cells, a T cell stimulation step (see below), e.g. using CD3 / CD28 antibodies coated on magnetic beads or artificial antigen presenting cells (aAPCs) expressing, e.g., anti-CD3 and anti-CD28 antibody fragments bound to the cell surface, can be further performed to stimulate the T cells and deplete other cells, e.g., B cells. The T cells of the enriched T cell preparation can then be subjected to genetic modification.

[0269] Instead of peripheral blood, tissues including bone marrow, lymph nodes, spleen, and tumors can be used as sources of T cells and NK cells. The T cells and NK cells can be from humans, primates, hamsters, rabbits, rodents, cows, pigs, sheep, horses, goats, dogs, or cats, although any other mammalian cells may be used. In certain embodiments of either aspect, the T or NK cells are human.

[0270] Mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells)) can be engineered to contain any of the CAR polypeptides described herein (e.g., a CAR polypeptide of SEQ ID NO: 10, 11, 12, or 13); or a nucleic acid encoding any of the CAR polypeptides described herein (e.g., a nucleic acid encoding a CAR polypeptide of SEQ ID NO: 10, 11, 12, or 13).

[0271] The invention further provides compositions and methods for treating and preventing diseases and conditions, including, for example, cancer, an autoimmune disease or disorder, or a plasma cell disease or disorder. These methods include the use of mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells)) that contain a CAR polypeptide described herein, or a nucleic acid encoding said CAR, and include administering the modified mammalian cells to a subject, e.g., to treat cancer. In some embodiments of any of the aspects, the modified mammalian cells (e.g., iPSCs or immune cells (e.g., T cells or NK cells) that contain one or more additional modifications described herein) are stimulated and / or activated prior to administration to the subject.

[0272] [Treatment method] The anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein may be useful for treating a disease or disorder in a subject, such as cancer, an autoimmune disorder, or a plasma cell dyscrasia or disorder.

[0273] As used herein, "cancer" refers to the hyperproliferation of cells whose unique traits, loss of normal cellular control, results in unregulated growth, lack of differentiation, local tissue invasion, and metastasis. As used herein, the term "tumor" refers to the abnormal proliferation of cells or tissues, for example, of malignant or benign types. Examples of cancer include, but are not limited to, glioblastoma, prostate cancer, glioma, leukemia, lymphoma, multiple myeloma, or solid tumors, such as lung cancer and pancreatic cancer. Non-limiting examples of leukemia include acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). In one embodiment, the cancer is ALL or CLL. Non-limiting examples of lymphomas include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma, Burkitt's lymphoma, hairy cell leukemia (HCL), and T-cell lymphomas (e.g., peripheral T-cell lymphomas (PTCL), including cutaneous T-cell lymphoma (CTCL) and anaplastic large cell lymphoma (ALCL)). In one embodiment, the cancer is DLBCL or follicular lymphoma. Non-limiting examples of solid tumors include adrenal cortical tumors, alveolar soft part sarcoma, carcinoma, chondrosarcoma, colorectal carcinoma, desmoid tumor, desmoplastic small round cell tumor, endocrine tumors, endodermal sinus tumor, epithelioid hemangioendothelioma, Ewing's sarcoma, germ cell tumors (solid tumors), giant cell tumor of bone and soft tissue, hepatoblastoma, hepatocellular carcinoma, melanoma, nephroma, neuroblastoma, non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), osteosarcoma, paraspinal sarcoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, synovial sarcoma, and Wilms' tumor. Solid tumors can be found in bone, muscle, or organs and can be sarcomas or carcinomas.

[0274] As used herein, an "autoimmune disease or disorder" is characterized by the inability of a person's immune system to distinguish between foreign and normal cells. This results in a person's immune system targeting a person's normal cells for programmed cell death. Non-limiting examples of autoimmune diseases or disorders include inflammatory arthritis, type 1 diabetes, multiple sclerosis, psoriasis, inflammatory bowel disease, SLE, and vasculitis, allergic inflammation, such as allergic asthma, atopic dermatitis, and contact hypersensitivity. Other examples of autoimmune diseases or disorders include, but are not limited to, transplant rejection, graft-versus-host disease, hemophilia with factor inhibitors, rheumatoid arthritis, multiple sclerosis (MS), systemic lupus erythematosus, Graves' disease (hyperthyroidism), Hashimoto's thyroiditis (hypothyroidism), celiac disease, Crohn's disease and ulcerative colitis, Guillain-Barre syndrome, primary biliary sclerosis / cirrhosis, sclerosing cholangitis, autoimmune hepatitis, Raynaud's phenomenon, scleroderma, Sjogren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis , polymyalgia rheumatica, temporal arteritis / giant cell arteritis, chronic fatigue syndrome (CFS), psoriasis, autoimmune Addison's disease, ankylosing spondylitis, acute disseminated encephalomyelitis, antiphospholipid syndrome, aplastic anemia, idiopathic thrombocytopenic purpura, myasthenia gravis, opsoclonus-myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus, pernicious anemia, polyarthritis in dogs, Reiter's syndrome, Takayasu's arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis and fibromyalgia (FM).

[0275] Plasma cells are white blood cells generated from B lymphocytes that function to produce and release antibodies required to fight infection. As used herein, a "plasma cell dyscrasia or disorder" is characterized by abnormal proliferation of plasma cells. Abnormal plasma cells can "crowd out" normal plasma cells, reducing their ability to fight foreign substances such as viruses or bacterial cells. Non-limiting examples of plasma cell dyscrasias or disorders include plasma cell dysplasia, plasmacytoma, plasma cell leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, isolated plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

[0276] Exemplary cancers that can be treated by the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein include cancers that contain cells that express TACI, such as multiple myeloma. Exemplary autoimmune diseases that can be treated by the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein include autoimmune diseases characterized by high titers of antibodies that contribute to the autoimmune disorder. For example, the autoimmune disease can be transplant rejection, graft-versus-host disease, or hemophilia with factor inhibitors. Plasma cell diseases or disorders that may be treated by the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein include plasma cell dysplasia, plasmacytoma, plasma cell leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, isolated plasmacytoma, extramedullary plasmacytoma, osteosclerosing myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. In certain embodiments, the subject is refractory to anti-BCMA therapy.

[0277] [Administration] In some embodiments, the methods described herein relate to treating a subject having or diagnosed as having cancer, a plasma cell dyscrasia or disorder, or an autoimmune disease or disorder with a mammalian cell comprising any of the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein. For example, the anti-TACI CARs described herein comprise any of the anti-TACI CAR polypeptides (and optional antibody reagents or cytokines) described herein, or a mammalian cell comprising a nucleic acid encoding any of the anti-TACI CAR polypeptides (and optional antibody reagents or cytokines) described herein. Subjects having cancer, a plasma cell dyscrasia or disorder, or an autoimmune disease or disorder can be identified by a physician using the present methods of diagnosing the condition. Symptoms and / or complications of the condition that characterize and aid in the diagnosis of these conditions are well known in the art and include, but are not limited to, fatigue, persistent infection, and persistent bleeding. For example, tests that may aid in the diagnosis of a condition include, but are not limited to, blood tests and bone marrow tests, as are known in the art for a given condition. A family history of a condition, or exposure to a risk factor for a condition, can also help determine whether a subject is likely to have the condition or make a diagnosis of the condition.

[0278] The compositions described herein may be administered to a subject having or diagnosed with a condition. In some embodiments, the methods described herein include administering to a subject an effective amount of the activated CAR T cells described herein to alleviate symptoms of the condition. As used herein, "alleviating symptoms of a condition" refers to ameliorating any condition or symptoms associated with the condition. Such reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more as measured by any standard technique, compared to an equivalent untreated control. Various means for administering the compositions described herein to a subject are known to those of skill in the art, including oral, parenteral, intrapulmonary, and intranasal, as well as intralesional administration when desired for localized treatment. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In one embodiment, the compositions described herein are administered systemically or locally. In a preferred embodiment, the compositions described herein are administered intravenously. In another embodiment, the compositions described herein are administered to the site of a tumor. Dosing can be by any suitable route, for example, injections, such as intravenous or subcutaneous injections, depending in part on whether administration is brief or chronic. A variety of dosing schedules are contemplated herein, including, but not limited to, single or multiple administrations over various time periods, bolus administrations, and pulse infusions.

[0279] Effective doses, toxicity, and therapeutic effects can be evaluated by standard pharmaceutical procedures in cell cultures or experimental animals. Dosages can vary depending on the dosage form used and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Compositions and methods that exhibit large therapeutic indices are preferred. Therapeutically effective doses can be estimated initially from cell culture assays. A dose can also be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of activated CAR T cells that achieves half-maximal inhibition of symptoms) determined in cell culture or a suitable animal model. Plasma levels can be measured, for example, by high performance liquid chromatography. The effect of any particular dosage can be monitored by suitable bioassays, such as, inter alia, assays for bone marrow biopsy. Dosages can be determined by a physician and adjusted as necessary to accommodate observed therapeutic effects.

[0280] In one aspect of the technology described herein, the technology described herein relates to a pharmaceutical composition comprising the activated CAR T cells described herein and, optionally, a pharma- ceutically acceptable carrier. The active component of the minimal pharmaceutical composition comprises the activated CAR T cells described herein. In some embodiments, the active component of the pharmaceutical composition consists essentially of the activated CAR T cells described herein. In some embodiments, the active component of the pharmaceutical composition consists of the activated CAR T cells described herein. Pharmaceutically acceptable carriers for cell-based therapeutic formulations include saline and aqueous buffers, Ringer's solution, and serum components, such as serum albumin, HDL, and LDL. Terms such as "additives," "carriers," "pharma- ceutically acceptable carriers," and the like, are used interchangeably herein.

[0281] In some embodiments, the pharmaceutical composition comprising the activated CAR T cells described herein can be in a parenteral dosage form. Since administration of a parenteral dosage form typically circumvents the patient's natural defense against contaminants, components other than the CAR T cells themselves are preferably sterile or can be sterilized before administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions for injection, dry products dissolved or suspended in a pharma- ceutically acceptable vehicle for injection, suspensions for injection, and emulsions. Any of these can be added to the activated CAR T cell preparation before administration.

[0282] Suitable vehicles that can be used to provide parenteral dosage forms of the disclosed activated CAR T cells are well known to those of skill in the art. Examples include, but are not limited to, saline; glucose solutions; aqueous vehicles including, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0283] [Dosage] The term "unit dosage form" as used herein means a dosage amount suitable for single administration. By way of example, a unit dosage form can be an amount of a therapeutic agent disposed in a delivery device, such as a syringe or an intravenous drip bag. In one embodiment, a unit dosage form is administered in a single dose. In another embodiment, more than one unit dosage form can be administered simultaneously.

[0284] In some embodiments, the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein are administered as monotherapy, i.e., no other treatment for the condition is concurrently administered to the subject.

[0285] As a general proposition, a therapeutically effective amount of anti-TACI antibody, antibody drug conjugate, and / or BiTE administered to a human is in the range of about 0.01 to about 100 mg / kg of the patient's body weight, whether administered in one or multiple doses. In some embodiments, the antibody used is administered in an amount of about 0.01 to about 45 mg / kg, about 0.01 to about 40 mg / kg, about 0.01 to about 35 mg / kg, about 0.01 to about 30 mg / kg, about 0.01 to about 25 mg / kg, about 0.01 to about 20 mg / kg, about 0.01 to about 15 mg / kg, about 0.01 to about 10 mg / kg, about 0.1 to about 10 mg / kg, or about 1 to about 10 mg / kg, either once (single dose) or many times (multiple doses, e.g., daily doses). In one example, the antibody used is about 10 mg / kg, preferably administered orally. In one embodiment, the anti-TACI antibodies, antibody drug conjugates, and / or BiTEs described herein are administered to a human on day 1 of a 21-day cycle at a flat dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, or about 1400 mg. The dose may be administered as a single dose or as multiple doses (e.g., two or three doses), such as by infusion. For repeated administration over several days or more, depending on the condition, treatment will generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be in the range of about 0.01 mg / kg to about 10 mg / kg. Such doses may be administered intermittently, e.g., every week or every three weeks (e.g., so that the patient receives from about 2 to about 20, or e.g., about 6 doses of the anti-TACI antibody, antibody drug conjugate complex, and / or BiTE). An initial higher loading dose, followed by one or more lower doses, may be administered. The progress of this therapy is easily monitored by conventional techniques and assays.

[0286] On the other hand, pharmaceutical compositions comprising mammalian cells containing the anti-TACI CAR described herein generally comprise at least 10 4 From 10 9 Cells / kg body weight, in some cases 10 5 From 106 The cells can be administered in dosages of cells / kg body weight, including all integer values ​​within those ranges. If necessary, the cell composition can also be administered multiple times at these dosages. The cells can be administered by using infusion techniques commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. Med. 319:1676, 1988). In some instances, it may be desirable to administer the activated CAR T cells to the subject, then redraw blood (or perform apheresis), activate T cells therefrom as described herein, and reinfuse the patient with these activated and expanded T cells. This method can be performed multiple times, every few weeks. In certain embodiments, the T cells can be activated from a blood draw of 10cc to 400cc. In certain embodiments, the T cells are activated from a blood draw of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, or 100cc. The method of administration can include, for example, intravenous (iv) injection or infusion. The compositions described herein may be administered to a patient intraarterially, intratumorally, intranodally, or intramedullarily. In some embodiments, the T cell compositions may be injected directly into a tumor, lymph node, or site of infection. In one embodiment, the compositions described herein are administered into a body cavity or fluid (e.g., ascites, pleural fluid, peritoneal fluid, or cerebrospinal fluid).

[0287] In certain exemplary aspects, the subject may undergo leukapheresis, where leukocytes are collected, enriched, or ex vivo removed to select and / or isolate cells of interest, e.g., T cells. These T cell isolates are expanded by contact with artificial APCs, e.g., aAPCs expressing anti-CD28 and anti-CD3 CDRs, and processed to allow for the introduction of one or more CAR constructs of the present technology, thereby generating CAR T cells. The subject in need thereof may then undergo standard treatment with high-dose chemotherapy, followed by a peripheral blood stem cell transplant. After or simultaneously with the transplant, the subject may receive an infusion of the expanded CAR T cells. In one embodiment, the expanded cells are administered before or after surgery.

[0288] In some embodiments, lymphodepletion is performed on the subject prior to administration of one or more CAR T cells described herein. In such embodiments, lymphodepletion can include administering one or more of melphalan, cytoxan, cyclophosphamide, and fludarabine.

[0289] Dosages of the above therapeutic agents administered to a patient will vary according to the exact nature of the condition being treated and the recipient of the treatment. Scaling of dosages for administration to humans can be performed in accordance with art-recognized practices.

[0290] In some embodiments, a single treatment regimen is required. In other cases, one or more subsequent doses or treatment regimen administrations may be performed. For example, after treatment every other week for three months, treatment may be repeated once a month for six months or for a year or more. In some embodiments, no additional treatment is administered after the first treatment.

[0291] The dosage of the compositions described herein can be determined by a physician and adjusted as necessary to suit the observed therapeutic effect. With regard to the duration and frequency of treatment, a skilled clinician will typically monitor the subject to determine when the treatment produces a therapeutic effect and to determine whether to administer further cells, discontinue treatment, resume treatment, or make other changes to the treatment regimen. The dosage should not be so high as to cause adverse side effects, such as cytokine release syndrome. In general, the dosage will vary depending on the age, medical condition, and sex of the patient, and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complications.

[0292] [Combination therapy] The anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein can optionally be used in combination with each other and with other known drugs and therapies, as can be determined to be appropriate by one of skill in the art. In one example, two or more different types of CARs targeting different cancer antigens (e.g., TACI and BCMA) can be administered in combination.

[0293] As used herein, administered "in combination" means that two (or more) different therapeutic agents are delivered to a subject during the course of the subject's affliction with a disorder, e.g., two or more therapeutic agents are delivered after the subject is diagnosed with a disorder and before the disorder is cured or eliminated, or before treatment is discontinued for other reasons. In some embodiments, the delivery of one therapeutic agent is still occurring when the delivery of the second begins, and there is an overlap in administration. This is sometimes referred to herein as "simultaneous" or "concurrent delivery." In other embodiments, the delivery of one therapeutic agent ends before the delivery of the other begins. In some embodiments in either case, the treatment is more effective due to the combined administration. For example, the second therapeutic agent is more effective than would be observed if administered in the absence of the first therapeutic agent, e.g., the same effect is observed with less of the second therapeutic agent, or the second therapeutic agent significantly reduces symptoms, or a similar situation is observed as with the first therapeutic agent. In some embodiments, the delivery is such that the reduction in symptoms or other parameters associated with the disorder is greater than would be observed with one therapeutic agent in the absence of the other therapeutic agent. The effects of the two therapeutic agents may be partially additive, fully additive, or greater than additive. Delivery may be such that the effect of the first therapeutic agent delivered is still detectable when the second therapeutic agent is delivered. The anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein and at least one additional therapeutic agent may be administered simultaneously, in the same or separate compositions, or sequentially. In the case of sequential administration, the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein may be administered first and the additional agent may be administered a second time, or the order of administration may be reversed. The anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CAR therapeutic agents and / or other therapeutic agents, procedures, or modalities may be administered during periods of active disease or during periods of remission or less active disease. The anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR therapy may be administered prior to another treatment, concurrently with a treatment, after a treatment, or during remission of a disorder.

[0294] When administered in combination, the anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR therapy and additional agent (e.g., second or third agent), or all, may be administered in amounts or dosages that are greater than, less than, or the same as the amount or dosage of each agent used individually, for example, as monotherapy. In certain embodiments, the amount or dosage of the activated CAR T cells, additional agent (e.g., second or third agent), or all administered is less than the amount or dosage of each agent used individually (e.g., at least 20%, at least 30%, at least 40%, or at least 50%). In other embodiments, the amount or dosage of the activated CAR T cells, additional agent (e.g., second or third agent), or all that results in a desired effect (e.g., treatment of cancer) is less than the amount or dosage of each agent individually required to achieve the same therapeutic effect (e.g., at least 20%, at least 30%, at least 40%, or at least 50% less). In further embodiments, the activated CAR T cells described herein may be used in a treatment regimen in combination with surgery, chemotherapy, radiation, mTOR pathway inhibitors, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytotoxin, fludarabine, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, or peptide vaccines, such as those described in Izumoto et al., J. Neurosurg. 108:963- 971, 2008.

[0295] In one example, the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein may be used in combination with checkpoint inhibitors. Exemplary checkpoint inhibitors include anti-PD-1 inhibitors, anti-CTLA4 inhibitors, anti-PDL1 inhibitors, and anti-TIM3 inhibitors.

[0296] In another embodiment, the anti-TACI antibodies, antibody drug conjugates, BiTEs, and / or anti-TACI CARs described herein can be used in combination with a chemotherapeutic agent.

[0297] [Effectiveness] For example, the efficacy of an anti-TACI antibody, antibody drug conjugate, BiTE, and / or anti-TACI CAR in treating a condition described herein or in inducing a response described herein (e.g., reduction in cancer cells) can be determined by a skilled clinician. However, a treatment is considered to be "effective treatment" as that term is used herein if, following treatment with the methods described herein, one or more of the signs or symptoms of a condition described herein are beneficially altered, other clinically acceptable symptoms are improved or even ameliorated, or a desired response is induced, for example, by at least 10%. Efficacy can be assessed, for example, by measuring a marker, indicator, symptom, and / or incidence or any other suitable measurable parameter of a condition treated by the methods described herein. Treatment with the methods described herein can reduce the level of a marker or symptom of a condition, for example, by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% or more.

[0298] Efficacy can also be measured by the absence of an individual's deterioration as assessed by hospitalization or the need for medical intervention (i.e., cessation of disease progression). Methods for measuring these indicators are known to those of skill in the art and / or described herein.

[0299] Treatment includes any treatment of a disease in an individual or animal (some non-limiting examples include humans or animals), including (1) inhibiting the disease, e.g., preventing the worsening of symptoms (e.g., pain or inflammation); or (2) reducing the severity of symptoms, e.g., causing regression of symptoms. An effective amount for the treatment of a disease means an amount sufficient to effect effective treatment, as that term is defined herein, for that disease, when administered to a subject in need thereof. The efficacy of an agent may be determined by assessing physical indicators of the disease state or desired response. It is well within the capabilities of one of ordinary skill in the art to monitor the efficacy of administration and / or treatment by measuring any one of such parameters, or any combination of parameters. The efficacy of a given approach can be evaluated in animal models of the disease states described herein. When using experimental animal models, the efficacy of the treatment is demonstrated when a statistically significant change in the marker is observed.

[0300] All patents and other publications, including literature references, issued patents, published patent applications, and co-pending patent applications, cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that may be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of this application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by reason of prior art or for any other reason. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicants and do not constitute any admission as to the accuracy of the dates or contents of these documents.

[0301] The description of the embodiments of the present disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. Although specific embodiments and examples of the present disclosure are described herein for illustrative purposes, those skilled in the relevant art will recognize that various equivalent modifications are possible within the scope of the present disclosure. For example, while method steps or functions are presented in a given order, in alternative embodiments, the functions may be performed in a different order, or may be performed substantially simultaneously. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the present disclosure can be modified, as appropriate, to provide still further embodiments of the present disclosure using the compositions, functions, and concepts of the above references and applications. Furthermore, considerations of biological function equivalence allow for some modifications to protein structures without affecting biological or chemical action in type or amount. These and other modifications can be made to the present disclosure in light of the detailed description. All such modifications are intended to be within the scope of the appended claims.

[0302] Specific elements of any of the foregoing embodiments can be combined with or substituted for elements of other embodiments. Additionally, although advantages associated with certain embodiments of the present disclosure have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments necessarily exhibit such advantages in order to fall within the scope of the present disclosure.

[0303] The technology described herein is further illustrated by the following examples, which should not be construed as further limiting in any way. EXAMPLES

[0304] The following are examples of useful methods and compositions: It will be understood that various other embodiments may be practiced in light of the description provided herein.

[0305] Example 1: Preparation of anti-TACI antibodies We generated monoclonal antibodies (mAbs) that specifically bind to transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). First, mAb-producing cells (i.e., hybridomas) were generated by fusing myeloma cells with B cells. After cell fusion, multiple clones were screened and selected based on antigen specificity and immunoglobulin class. Once candidate hybridoma cell lines were identified, the antibodies were validated and characterized using several downstream functional assays (Figure 1). The mAbs were sequenced and the variable heavy (VH) and variable light (VL) chains were used to generate second-generation chimeric antigen receptors.

[0306] The antibodies were analyzed by surface plasmon resonance according to the following procedure (Figure 2): Binding of his-tagged recombinant TACI to anti-TACI antibodies was captured with anti-mouse IgG to 120 RU (for TACI). Capture: Antibodies were brought to 1 mg / mL in running buffer and captured onto an anti-mouse IgG surface (CM5 chip, 10000 RU of anti-IgG antibody immobilized by standard amine-directed chemistry according to manufacturer's instructions, GE Healthcare, catalog no. BR-1008-38) to achieve 130 RU for TACI analysis. Running buffer: PBS-P (10 mM sodium phosphate, 150 mM NaCl, 0.005% Tween 20, pH 7.4). Renaturation buffer: 10 mM glycine, pH 2.1 Flow rate and injection scheme: Flow rate: 50 mL / min, 2 min contact time, 5 min dissociation

[0307] The results of the assay are shown in Figure 2. Results: a (Binding rate constant)=1.407×10 6 1 / Ms, k d (dissociation rate constant)=0.00121 1 / s, K D (Equilibrium dissociation constant)=8.61×10 -10M, Rmax (maximum binding amount (fit)) = 31.28 RU, and Chi 2 =0.943RU 2 . RU: Resonance unit.

[0308] Example 2 Design of anti-TACI chimeric antigen receptor (CAR) Second generation chimeric antigen receptors (CARs) were designed as shown in Figure 3. Two anti-TACI CAR constructs were generated, one containing a VH at the N-terminus of the VL of an anti-TACI single chain variable fragment (scFv) (anti-TACI(H / L)) and the other containing a VL at the N-terminus of the VH of an anti-TACI scFv (anti-TACI(L / H)). The VH and VL sequences contained in the CARs were derived from the anti-TACI antibody described in Example 1. Each CAR further contains a CD8 hinge / transmembrane domain, a 4-1BB costimulatory domain, and a CD3 zeta intracellular signaling domain. The CARs were expressed in T cells according to standard methods (see Example 3 et seq.). To test the potential effect of anti-TACI antibodies on immune cells, peripheral blood mononuclear cells (PBMCs) were incubated with anti-TACI antibodies and binding was measured by flow cytometry. Results demonstrated that anti-TACI antibodies did not bind to isolated T cells (resting or activated) or various other PBMCs (Figure 23). K562, which overexpresses TACI, was used as a positive control.

[0309] To evaluate the expression, binding efficiency, and binding specificity of the anti-TACI CARs, normal donor T cells were transduced with anti-TACI HL, anti-TACI LH, or anti-BCMA, and transduction efficiency was assessed by measuring the percentage of each cell population positive for mCherry expression by flow cytometry. The results demonstrated that the transduction efficiency of both anti-TACI CAR constructs was high and similar to that of the anti-BCMA CAR (Figure 24). To compare the binding efficiency and specificity of the different CARs, T cells expressing each CAR construct were incubated with fluorescently labeled soluble TACI and analyzed by flow cytometry. The results demonstrated that the anti-TACI LH CAR had a higher binding affinity to soluble TACI than the anti-TACI HL CAR, and the anti-BCMA CAR showed no binding to the soluble TACI protein (Figures 25A and 25B).

[0310] To further evaluate the specificity of the anti-TACI CARs against TACI, MM1S cancer cells expressing Cas9 were generated. Cells expressing TACI or lacking TACI via Cas9 knockout were generated. Figure 27A shows that Cas9 knockout of TACI was successful. MM1S Cas9 and MM1S Cas9 TACI knockout (KO) cells were incubated with T cells that were untransduced or transduced with anti-TACI HL, anti-TACI LH, or anti-BCMA, and cytotoxicity was measured. The results demonstrate that the anti-TACI CARs are specific for TACI, and T cells expressing them had little efficacy against TACI KO cells, whereas only the positive control anti-BCMA CAR T cells had substantial cytotoxicity (Figure 27B).

[0311] Example 3 Expression of BCMA and TACI antigens The multiple myeloma cell line MM1S was used in the experiments described here. MM1S expresses both TACI and B cell maturation antigen (BCMA). A BCMA knockout MM1S cell line was generated, as well as K562 cell lines expressing TACI and K562 cell lines expressing BCMA (Figure 4). Since TACI is expressed in activated T cells, we assessed whether resting CAR T cells or activated CAR T cells (activated with beads) express or upregulate TACI expression. As shown in Figure 5, there is some expression in resting cells, but very little change is seen when CAR T cells are activated.

[0312] Example 4 Transfection efficiency and killing activity of anti-TACI CAR T cells The transfection efficiency of anti-TACI CAR T cells is measured by quantification of mCherry positive cells, since the CAR T cells are engineered to express mCherry (see Figure 3). As can be seen in Figure 6, the transfection efficiency of the anti-BCMA-BBz CAR is very similar to that of both TACI CARs. Target multiplicity of infection (MOI) = 10. A killing assay was performed to evaluate the activity of anti-TACI (H / L) and (L / H) CAR T cells compared to anti-BCMA CAR and untransduced (UTD) T cells. The results of the assay are shown in Figure 7. CAR T cells were incubated overnight with target cells at various effector:target (E:T) ratios shown in Figure 7. The target cells used were MM1S cells expressing both BCMA and TACI. Anti-BCMA CAR and both anti-TACI CAR T cells were demonstrated to be superior killers. At low E:T ratios, anti-TACI (L / H) CAR T cells appeared to be more efficient.

[0313] Similar killing assays were performed with the anti-BCMA CAR, anti-TACI(H / L)CAR, anti-TACI(L / H)CAR, and UTD T cells described above using as target cells the MM1S BCMA knockout cell line generated in Example 3. It was observed that while the anti-BCMA CAR T cells were unable to kill the MM1S BCMA knockout cell line, both anti-TACI CAR T cells specifically recognized TACI and killed the target (Figure 8).

[0314] Example 5 Immunophenotyping of CAR T cells Figure 9 shows T cells labeled with CD45RO and CCR7, allowing characterization of four functionally distinct populations: naive, central memory (CM), effector memory (EM), and late effector (EMRA) T cells. As typically observed with second generation 4-1BB CARs, the CM population of T cells is enriched. Similar results were observed when comparing anti-BCMA CARs to both anti-TACI CARs. A population previously described as important for long-term memory in the immune system is the T stem cell memory (TSCM) population, which is defined by specific markers from the naive population (CD45-CCR7+) shown in Figure 9. Markers specific for the TSCM population are CD95C and D127. Figure 10 shows that anti-TACI CAR T cells have a TSCM population.

[0315] Example 6. CAR T cell degranulation and specific binding BCMA and TACI CAR T cells were stained with anti-CD107a antibody (protein transporter inhibitors added), left alone (negative control: -CL), co-cultured with different targets for 6 hours, or activated with PMA / ionomycin (positive control: +CL). Flow cytometry was performed, gated on live CAR T cells, to evaluate the expression of CD107a, a marker of cytotoxic degranulation. The results are shown in Figure 11. Anti-TACI CAR T cells were observed to degranulate specifically in response to TACI+ targets, but not BCMA+ / TACI- targets.

[0316] Anti-BCMA, anti-TACI(H / L), and anti-TACI(L / H) CAR T cells were assessed and determined for their ability to bind soluble TACI (sTACI), soluble BCMA (sBCMA), and soluble APRIL (sAPRIL). T cells were washed four times with 4% BSA in PBS and incubated with labeled proteins on ice for 40 minutes at 4°C. After incubation, cells were washed twice with FACS buffer and flow cytometry was performed gating on live CAR T cells and protein binding was calculated. The results are shown in Figures 12A-12C. As can be seen in Figure 12A, anti-TACI(L / H) CAR T cells have a higher binding efficiency to soluble TACI than anti-TACI(H / L) CAR T cells. In Figure 12B, the binding of both anti-TACI CAR T cells to BCMA is demonstrated to be negligible. Finally, FIG. 12C shows that anti-BCMA and both anti-TACI CART cells have similar binding efficiencies to soluble APRIL.

[0317] Example 7 Cytokine production and long-term proliferation of anti-TACI CAR T cells Cytokine production of anti-BCMA and both anti-TACI CAR T cells was assessed by incubating CAR T cells with specific targets (MM1S or MM1S BCMA knockout cell lines). Non-transduced cells were used as controls. The levels of cytokine production are shown in Figures 13A and 13B. Anti-TACI CAR T cells were demonstrated to produce cytokines in response to both MM1S and MM1S BCMA knockout cells. Similarly, cytokine production of anti-BCMA and both anti-TACI CAR T cells was assessed, but this time using K562-TACI and K562-BCMA cell lines as targets (Figures 13C and 13D). Both anti-TACI CAR T cells produce more cytokines in response to TACI-expressing targets than in response to BCMA-expressing targets. Finally, cytokine production of CAR T cells was assessed with U266 cells, another multiple myeloma cell line. The results are shown in Figure 13E. Furthermore, it was demonstrated that anti-TACI CAR T cells can undergo long-term proliferation in vitro when stimulated with K562 target cells. CAR T cells were stimulated on the days indicated by the arrows, and the population doublings of CAR T cells are shown in Figure 14.

[0318] Example 8 Anti-TACI CAR T cells in vivo The experimental design of the in vivo experiment using anti-TACI CAR T cells is shown in Figure 15. Mice were injected intravenously (iv) with 1 million MM1S cells. Two weeks later, mice were injected with 2 million CAR T cells or UTD cells. Images were taken twice a week and bioluminescence was quantified. Bioluminescence images are shown in Figures 16A and 16B. In Figure 17, bioluminescence was quantified in photons / second and is shown in four graphs for each CAR T cell used. As shown in Figure 18, anti-TACI (L / H) CAR T cells are as effective as anti-BCMA CAR T cells in treating BCMA+ / TACI+ multiple myeloma. Figure 19 shows the ability of anti-TACI CAR T cells to be curative in TACI+ multiple myeloma.

[0319] The design of additional in vivo experiments using anti-TACI CAR T cells is shown in Figure 26A. 6 RPMI8226 cells were subcutaneously implanted into mice. Two weeks later, mice were implanted with 2 × 10 6CAR T cells or non-transduced cells were injected intravenously or left untreated. Tumor volumes were measured by caliper at 4, 7, 10, and 14 days after CAR T treatment. Individual tumor growth curves are shown in Figures 26B, 26C, 26D, 26E, and 26F. Figure 26G shows the survival rate of mice in each treatment group. The results show that anti-TACI CAR T cells are effective in vivo in a subcutaneous tumor growth model in both suppressing tumor growth and prolonging survival, suggesting that the LH construct may be more effective than the HL construct. Figure 26H further shows that anti-TACI LH CAR T cells show proliferation in the blood at day 21. Anti-BCMA CAR T cells served as a positive control, and non-transduced and tumor-only groups served as negative controls.

[0320] Example 9 Overcoming antigen loss in hematological malignancies with CAR T cell therapy Currently, one of the most promising candidates for CAR T cell therapy beyond CAR19 (CAR targeting CD19) is the treatment of multiple myeloma with CAR T cells targeting B-cell maturation antigen (BCMA), a member of the TNF receptor superfamily. Multiple myeloma accounts for 13% of all hematological malignancies and there is an unmet clinical need for new therapies. Current reports of BCMA CARs in the clinic have a median progression-free survival of 11.8 months, suggesting that targeting BCMA alone is insufficient. Similar to what is observed with CAR19 treatment and CD19-negative relapse, evidence suggests that patients treated with BCMA-targeted therapy may be hampered by BCMA-negative relapse. In CD19+ malignancies, there are many approaches to overcome CD19-negative malignancies, including tandem CAR T cells targeting two antigens, such as CD19 and CD20, or CD19 and CD22. In multiple myeloma, a plausible target beyond BCMA is transmembrane activator and CAML interactor (TACI). Like BCMA, TACI is also a member of the TNF receptor superfamily and provides survival signals to plasma cells. This antigen is targeted with CAR T cells using the proliferation-inducing ligand (APRIL), a natural ligand that also recognizes BCMA. Currently, there are no published CAR T cells that target TACI exclusively. To date, there is no direct comparison of scFv-based dual-targeting CAR T cells and natural ligand designs.

[0321] By immunizing mice and constructing anti-TACI CARs from the resulting hybridomas, novel CAR T cells targeting TACI were designed and provided in this disclosure. There were two types of anti-TACI CARs based on the orientation of the variable heavy and variable light chains (Figure 20A). The anti-TACI CARs are functional in vitro against multiple myeloma lines MM1S and RPMI-8226, which are positive for both BCMA and TACI, and have lower activity against the TACI-low myeloma line U266 (Figures 20B-20C). In a transgenic model of multiple myeloma, the LH orientation of the scFv cured more quickly, and the LH CAR bound to soluble TACI more efficiently in vitro (Figures 20D-20E).

[0322] The anti-TACI CAR is functional in the presence of TACI antigen, but loses potency if the antigen is lost, similar to the BCMA CAR (Figure 21D-21E). To overcome the potential loss of antigen that is responsible for the failure of CAR19, we designed tandem bispecific CAR T cells that target both BCMA and TACI using anti-TACI scFv (VH-VL configuration). Engineered dual-targeting BCMA and TACI CARs were also designed based on their natural ligand APRIL (Figure 21A). This construct, named TriPRIL, had three repeat truncated APRIL ligands to form trimers that have been shown to be its secreted form. It was unclear which design of the dual-targeting CAR, tandem bispecific CAR, or natural ligand would be the more effective therapy. Despite the larger vector size, the transduction efficiency of the dual-targeting CAR construct was comparable to that of single-chain scFv in normal donor T cells (Figure 21B). In vitro cytotoxicity of the dual targeting tandem bispecific CAR was comparable to TriPRIL against MM1S and RPM1-8226 myeloma lines (Figure 21C). Anti-TACI-anti-BCMA bispecific and TriPRIL appear to have comparable functionality against the multiple myeloma line U266, which has low TACI expression (Figure 20B). Anti-BCMA-anti-TACI bispecific is less effective. In the antigen loss scenario, loss of BCMA shows the greatest difference with anti-TACI-anti-BCMA bispecific losing some potency (Figures 21D-21E). Supernatants from these assays were also collected to assess cytokine production.

[0323] Example 10 Bispecific CAR T cells for multiple myeloma: natural ligands compared to tandem scFv designs In Example 9, dual BCMA and TACI targeting CARs based on tandem scFv or natural ligand design were shown to have similar efficacy against wild-type multiple myeloma models. However, this changes in the context of loss of a single antigen. The proliferation (population doubling) and activation capacity (CD69) of these CARs, as well as their memory (CCR7, CD45RA) and exhaustion phenotypes (PD-1, Tim3, LAG-3) were characterized upon prolonged exposure to a single antigen. Sensitivity to antigen density was shown to differ between tandem bispecific CARs and natural ligand CARs. The results indicate that structural differences between dual-targeting CAR T cells affect their function. To test the efficacy of bispecific CAR T cells binding to each of their respective antigens, T cells were left untransduced or transduced with anti-TACI HL CAR, anti-TACI LH CAR, anti-BCMA CAR, anti-TACI / anti-BCMA bispecific CAR, or anti-BCMA / anti-TACI bispecific CAR and tested for their binding of soluble antigens. The results demonstrate that the bispecific CARs have lower binding affinity for their soluble antigens compared to their monospecific counterparts and that the orientation of the two components of the tested bispecific CARs does not affect their binding (Figure 28).

[0324] To test the effect of bispecific CARs on cytokine production in cancer cell / T cell cocultures, MM1S or RPMI8226 multiple myeloma cells were cultured alone or in coculture with non-transduced T cells, anti-TACI / anti-BCMA bispecific CAR-transduced T cells, or anti-BCMA / anti-TACI bispecific CAR-transduced T cells, and cytokines were measured in culture supernatants. Results demonstrate that bispecific CAR T cells produce interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor alpha (TNF-α) in response to multiple myeloma cell lines in vitro (Figure 29). The design of additional experiments using bispecific CAR T cells in vivo is shown in Figure 30A. 6Mice were intravenously (iv) injected with 2 × 10 MM1S multiple myeloma cells. Then, 2 weeks later, 6 CAR T cells were injected and bioluminescence imaging was performed to detect MM1S cell viability over time. Bioluminescence flux measurements over time in mice treated with untreated or untransduced T cells, or T cells transduced with anti-TACI / anti-BCMA bispecific CARs or anti-BCMA / anti-TACI bispecific CARs are shown in Figures 30B, 30C, and 30D for T cells from three different donors. A representative bioluminescence image from donor 1 is shown in Figure 30E. The results demonstrate that bispecific CAR T cells were functional against MM1S in vivo, with anti-BCMA / anti-TACI CAR T cells from 2 of 3 donors being effective and anti-TACI / anti-BCMA CAR T cells from 3 of 3 donors being effective.

[0325] Bispecific CAR T cells showed further efficacy in a subcutaneous tumor model of multiple myeloma. Figure 31A shows mice were inoculated with 5×10 6 Figure 32A shows the experimental design in which RPMI8226 cells were implanted subcutaneously, followed by intravenous injection of CAR T cells two weeks later. Tumor volumes were measured over time, and CAR T cells were counted in the blood on days 14 and 21 after injection. The results demonstrate that anti-BCMA / anti-TACI CAR T cells outgrow anti-TACI / anti-BCMA CAR T cells or non-transduced T cells in vivo (Figure 31B), and both CAR T cell types suppress subcutaneous tumor growth compared to non-transduced T cells or tumors in untreated mice (Figures 31C, 31D, 31E, and 31F). T cell exhaustion may contribute to the ineffectiveness of CAR T cells. To evaluate the exhaustion of bispecific CAR T cells, experiments were performed according to the timeline shown in Figure 32A. First, 1x10 ... 6T cells were plated. Flow cytometry analysis of Tim-3 and Lag3 exhaustion markers was performed on days 0, 7, 14, 21, and 28 after initial plating. At each time point, T cells were counted and 1 × 10 per condition were plated. 6 100 cells were plated and (re)stimulated with irradiated K562 cells overexpressing BCMA. Results demonstrate that anti-BCMA / anti-TACI bispecific CAR T cells express lower exhaustion markers Tim-3 and Lag3 upon repeated stimulation compared to anti-BCMA and anti-TACI / anti-BCMA bispecific CAR T cells, which may explain their greater potency against a single antigen.

[0326] T cell phenotype within the CAR T cell population was assessed according to the experimental design summarized in Figure 33A. CAR T cells expressing anti-BCMA CARs, anti-TACI / anti-BCMA bispecific CARs, or anti-BCMA / anti-TACI bispecific CARs were counted and cultured at 1 x 10 6Cells were plated and memory phenotype was quantified by flow cytometry every week. CAR T cells were characterized according to the four phenotypes shown on the left side of Figure 33B. Cells were classified as central memory (CM) if positive for CCR7 and negative for CD45RA; effector memory (EM) if negative for both CCR7 and CD45RA; well-differentiated effector (TDE) if negative for CCR7 and positive for CD45RA; or naive if positive for both CCR7 and CD45RA. See X. Wang et al., Blood (2016) 127(24):2980-2990; L. Gattinoni et al., Nat. Med. (2011) 17(10):1290-1297; and L. Biasco et al., Sci. Transl. Med. (2015) 7(273):273ra213. The results demonstrated that the majority of anti-BCMA / anti-TACI bispecific CAR T cells retained the central memory phenotype, rather than anti-TACI / anti-BCMA bispecific CAR T cells or anti-BCMA CAR T cells, which instead converted to an effector phenotype in the same time frame (Figure 33B). Little difference in proliferation between the groups was observed (Figure 33C).

[0327] JPEG0007584453000002.jpg202170JPEG0007584453000003.jpg187170JPEG0007584453000004.jpg167170JPEG0007584453000005.jpg2381 70JPEG0007584453000006.jpg177170JPEG0007584453000007.jpg86170JPEG0007584453000008.jpg72170JPEG0007584453000009.jpg76170

[0328] Some embodiments of the technology described herein may be defined according to any of the following numbered paragraphs: 1. An isolated antibody that specifically binds to transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), having a K of about 2 nM or less. D Antibody that binds to TACI. 2. The antibody has a K between about 500 pM and about 1 nM. D The antibody of claim 1, which binds to TACI at 3. The antibody has a K between about 700 pM and about 900 pM. D 3. The antibody of paragraph 1 or 2, which binds to TACI at 4. The antibody has a K of approximately 861 pM. D 4. The antibody of any one of paragraphs 1-3, which binds to TACI. 5. An isolated antibody that specifically binds to TACI, wherein the antibody comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1 and / or a light chain variable domain (VL) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2. 6. The antibody of paragraph 5, wherein the VH comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:1 and the VL comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:2. 7. The antibody of paragraph 5, wherein the VH comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1, and the VL comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2. 8. The antibody of paragraph 5, wherein the VH comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO:1, and the VL comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO:2. 9. The antibody of paragraph 5, wherein the VH comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:1, and the VL comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence of SEQ ID NO:2. 10. An isolated antibody that specifically binds to TACI, wherein the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2. 11. The antibody of any one of paragraphs 1-10, wherein the antibody is a monoclonal, human, humanized, or chimeric antibody. 12. The antibody of paragraph 11, wherein the antibody is a monoclonal antibody. 13. The antibody of any one of paragraphs 1-12, wherein the antibody is a full-length antibody. 14. The antibody of any one of paragraphs 1-12, wherein the antibody is an antibody fragment that specifically binds to TACI. 15. The antibody of paragraph 14, wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments. 16. The antibody of any one of paragraphs 1-15, wherein the antibody is an IgG antibody. 17. The antibody of paragraph 16, wherein the antibody is an IgG1 antibody. 18. A composition comprising the antibody of any one of paragraphs 1-17. 19. A polynucleotide encoding the antibody of any one of paragraphs 1-17. 20. A vector comprising the polynucleotide of paragraph 19. 21. A host cell comprising the vector of paragraph 16. 22. The host cell of paragraph 21, wherein the host cell is a mammalian cell. 23. The host cell of paragraph 22, wherein the mammalian cell is a Chinese Hamster Ovary (CHO) cell. 24. A host cell according to paragraph 21, wherein the host cell is a prokaryotic cell. 25. The host cell of paragraph 24, wherein the prokaryotic cell is Escherichia coli. 26. A method for producing an antibody that specifically binds to TACI, the method comprising culturing a host cell of any one of paragraphs 21-25 in a culture medium. 27. The method of paragraph 22, further comprising recovering the antibody from the host cell or culture medium. 28. An antibody drug conjugate comprising an antibody according to any one of paragraphs 1-27. 29. A chimeric antigen receptor (CAR) polypeptide comprising an extracellular target binding domain, wherein the extracellular target binding domain comprises a TACI binding domain. 30. The CAR polypeptide of paragraph 29, wherein the CAR polypeptide comprises a transmembrane domain and an intracellular signaling domain. 31. The CAR polypeptide of paragraph 29 or 30, further comprising one or more costimulatory domains. 32. The CAR polypeptide of any one of paragraphs 29-31, wherein the TACI binding domain does not include APRIL, BAFF, CAMLG, or any portion thereof. 33. The TACI binding domain has a K of approximately 2 nM or less. D 33. The CAR polypeptide of any one of paragraphs 29-32, which binds to TACI. 34. The TACI binding domain has a K between about 500 pM and about 1 nM. D 34. The CAR polypeptide of any one of paragraphs 29-33, which binds to TACI. 35. The TACI binding domain has a K between about 700 pM and about 900 pM. D 35. The CAR polypeptide of any one of paragraphs 29-34, which binds to TACI. 36. The TACI binding domain has a K of approximately 861 pM. D 36. The CAR polypeptide of any one of paragraphs 29-35, which binds to TACI. 37. The CAR polypeptide of any one of paragraphs 29-36, wherein the TACI binding domain comprises an antibody or an antigen-binding fragment thereof. 38. A CAR polypeptide comprising an extracellular target binding domain comprising the antibody or antigen-binding fragment thereof of any one of paragraphs 1-17. 39. The CAR polypeptide of any one of paragraphs 29-38, wherein the TACI binding domain comprises an anti-TACI single-chain variable fragment (scFv). 40. The CAR polypeptide of paragraph 39, wherein the anti-TACI scFv comprises a heavy chain variable domain (VH) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1. 41. The CAR polypeptide of paragraph 40, wherein the VH comprises the amino acid sequence of SEQ ID NO:1. 42. The CAR polypeptide of any one of paragraphs 39-41, wherein the anti-TACI scFv comprises a light chain variable domain (VL) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2. 43. The CAR polypeptide of paragraph 42, wherein the VL comprises the amino acid sequence of SEQ ID NO:2. 44. The CAR polypeptide of any one of paragraphs 39-43, wherein the anti-TACI scFv comprises a VH comprising the amino acid sequence of SEQ ID NO:1 and a VL comprising the amino acid sequence of SEQ ID NO:2. 45. The CAR polypeptide of any one of paragraphs 40-44, wherein the VH is located at the N-terminus of the VL. 46. ​​The CAR polypeptide of any one of paragraphs 40-44, wherein the VL is located at the N-terminus of the VH. 47. The CAR polypeptide of any one of paragraphs 40-46, wherein the VH and VL are linked via a linker sequence. 48. The CAR polypeptide of paragraph 47, wherein the linker sequence comprises the amino acid sequence of SEQ ID NO:3, 14, 15, 16, or 17. 49. The CAR polypeptide of paragraph 48, wherein the linker sequence comprises the amino acid sequence of SEQ ID NO:3. 50. The CAR polypeptide of any one of paragraphs 29-49, wherein the TACI binding domain comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 4 or 5. 51. The CAR polypeptide of paragraph 49 or 50, wherein the TACI binding domain comprises the amino acid sequence of SEQ ID NO:4 or 5. 52. The CAR polypeptide of any one of paragraphs 29-51, wherein the transmembrane domain comprises a hinge / transmembrane domain. 53. The CAR polypeptide of paragraph 52, wherein the hinge / transmembrane domain comprises the hinge / transmembrane domain of an immunoglobulin-like protein, CD28, CD8, or 4-1BB. 54. The CAR polypeptide of paragraph 53, wherein the hinge / transmembrane domain is the hinge / transmembrane domain of CD8, and optionally, the hinge / transmembrane domain of CD8 comprises the amino acid sequence of SEQ ID NO:7. 55. The CAR polypeptide of any one of paragraphs 29-54, wherein the intracellular signaling domain comprises an intracellular signaling domain of CD3ζ, CD3ε, or CD3θ. 56. The CAR polypeptide of paragraph 55, wherein the intracellular signaling domain comprises the intracellular signaling domain of CD3ζ, and optionally, the intracellular signaling domain of CD3ζ comprises the amino acid sequence of SEQ ID NO:9. 57. The CAR polypeptide of any one of paragraphs 31 to 56, wherein the costimulatory domain comprises a costimulatory domain of 4-1BB, CD28, CD27, ICOS, or OX40. 58. The CAR polypeptide of paragraph 57, wherein the costimulatory domain comprises a costimulatory domain of 4-1BB, and optionally, the costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO:8. 59. The CAR polypeptide of any one of paragraphs 29-58, wherein the CAR polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 10, 11, 12, or 13. 60. The CAR polypeptide of any one of paragraphs 29-58, wherein the extracellular target binding domain further comprises a target binding domain that binds to a second target that is not TACI. 61. The CAR polypeptide of paragraph 60, wherein the second target is B-cell maturation antigen (BCMA). 62. The CAR polypeptide of paragraph 60 or 61, wherein the target binding domain comprises a ligand of a second target. 63. The CAR polypeptide of paragraph 60 or 61, wherein the target binding domain comprises an antibody or an antigen-binding fragment thereof. 64. The CAR polypeptide of paragraph 63, wherein the antibody or antigen-binding fragment thereof comprises an scFv. 65. The CAR polypeptide of paragraph 64, wherein the scFv is an anti-BCMA scFv. 66. The CAR polypeptide of paragraph 65, wherein the anti-BCMA scFv is located N-terminus of the anti-TACI scFv. 67. The CAR polypeptide of paragraph 65, wherein the anti-TACI scFv is located N-terminal to the anti-BCMA scFv. 68. A CAR polypeptide comprising the amino acid sequence of SEQ ID NO:10. 69. A CAR polypeptide comprising the amino acid sequence of SEQ ID NO:11. 70. A CAR polypeptide comprising the amino acid sequence of SEQ ID NO:12. 71. A CAR polypeptide comprising the amino acid sequence of SEQ ID NO:13. 72. A polynucleotide encoding the CAR polypeptide of any one of paragraphs 29-71. 73. The polynucleotide of paragraph 72, further comprising a suicide gene. 74. The polynucleotide of paragraph 72 or 73, further comprising a sequence encoding a signal sequence. 75. A mammalian cell comprising the CAR polypeptide of any one of paragraphs 29-71 and / or the polynucleotide of any one of paragraphs 72-74. 76. The mammalian cell of paragraph 75, wherein the mammalian cell is an induced pluripotent stem cell (iPSC). 77. The mammalian cell of paragraph 75, wherein the mammalian cell is an immune cell. 78. The mammalian cell of paragraph 77, wherein the immune cell is a T cell or a natural killer (NK) cell. 79. The mammalian cell of any one of paragraphs 75-78, wherein the mammalian cell is a human cell. 80. A bispecific antibody that binds to TACI and CD3, comprising a TACI-binding domain and a CD3-binding domain. 81. The TACI binding domain has a K of approximately 2 nM or less. D81. The bispecific antibody of paragraph 80, which binds to TACI at 82. The TACI binding domain has a K between about 500 pM and about 1 nM. D 82. The bispecific antibody of paragraph 80 or 81, which binds to TACI at 83. The TACI binding domain has a K between about 700 pM and about 900 pM. D 83. The bispecific antibody of any one of paragraphs 80-82, which binds to TACI at 84. The TACI binding domain has a K of approximately 861 pM. D 84. The bispecific antibody of any one of paragraphs 80-83, which binds to TACI at 85. A bispecific antibody of any one of paragraphs 80-84, wherein the TACI binding domain comprises a VH comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:1, and / or a VL comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:2. 86. A bispecific antibody that specifically binds to TACI and CD3, comprising a TACI binding domain and a CD3 binding domain, wherein the TACI binding domain comprises a VH having the amino acid sequence of SEQ ID NO:1 and a VL having the amino acid sequence of SEQ ID NO:2. 87. The bispecific antibody of any one of paragraphs 80-86, wherein the TACI binding domain is located N-terminal to the CD3 binding domain. 88. The bispecific antibody of any one of paragraphs 80-86, wherein the CD3 binding domain is located N-terminal to the TACI binding domain. 89. The bispecific antibody of any one of paragraphs 80-88, wherein the TACI binding domain and the CD3 binding domain are linked by a linker sequence. 90. The bispecific antibody of paragraph 89, wherein the linker sequence comprises the amino acid sequence of SEQ ID NO:3, 14, 15, 16, or 17. 91. The bispecific antibody of any one of paragraphs 80-90, wherein the bispecific antibody is a monoclonal, human, humanized, or chimeric antibody. 92. The bispecific antibody of paragraph 91, wherein the bispecific antibody is a monoclonal antibody. 93. The bispecific antibody of any one of paragraphs 80-92, wherein the bispecific antibody is a full-length antibody. 94. The bispecific antibody of any one of paragraphs 80-92, wherein the bispecific antibody is an antibody fragment that specifically binds to TACI and CD3. 95. The antibody of paragraph 94, wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and (Fab')2 fragments. 96. The bispecific antibody of any one of paragraphs 80-95, wherein the bispecific antibody is an IgG antibody. 97. The bispecific antibody of paragraph 96, wherein the bispecific antibody is an IgG1 antibody. 98. A composition comprising the bispecific antibody of any one of paragraphs 80-97. 99. A polynucleotide encoding the bispecific antibody of any one of paragraphs 80-97. 100. A vector comprising the polynucleotide of paragraph 99. 101. A host cell comprising the vector of paragraph 100. 102. The host cell of paragraph 101, wherein the host cell is a mammalian cell. 103. The host cell of paragraph 102, wherein the mammalian cell is a Chinese Hamster Ovary (CHO) cell. 104. A host cell according to paragraph 101, wherein the host cell is a prokaryotic cell. 105. The host cell of paragraph 104, wherein the prokaryotic cell is Escherichia coli. 106. A method for producing a bispecific antibody that specifically binds to TACI and CD3, comprising culturing a host cell of any one of paragraphs 101-105 in a culture medium. 107. The method of paragraph 106, further comprising recovering the bispecific antibody from the host cell or culture medium. 108. A method of treating a disease or disorder in a subject in need of treatment, comprising administering to the subject one or more of: (i) a CAR polypeptide of any one of paragraphs 29-71, a polynucleotide of any one of paragraphs 19, 72-74, and 99, and / or a mammalian cell of any one of paragraphs 22, 23, 75-79, 102, and 103; (ii) an antibody of any one of paragraphs 1-17, (iii) an antibody drug conjugate of paragraph 28; and (iv) a bispecific antibody of any one of paragraphs 80-97. 109. The method of paragraph 108, wherein the disease or disorder is cancer, an autoimmune disorder, or a plasma cell dyscrasia or disorder. 110. The method of paragraph 109, wherein the disease or disorder is cancer. 111. The method of paragraph 110, wherein the cancer comprises cells that express TACI. 112. The method of paragraph 111, wherein the cancer is multiple myeloma. 113. The method of any one of paragraphs 110-112, wherein the subject is resistant to anti-BCMA therapy. 114. The method of paragraph 109, wherein the disease or disorder is an autoimmune disease or disorder. 115. The method of paragraph 114, wherein the autoimmune disease or disorder is characterized by high titers of antibodies that contribute to the autoimmune disorder. 116. The method of paragraph 114 or 115, wherein the autoimmune disease or disorder is graft rejection, graft-versus-host disease, or hemophilia with factor inhibitors. 117. The method of paragraph 109, wherein the disease or disorder is a plasma cell disease or disorder. 118. The method of paragraph 117, wherein the plasma cell disease or disorder is plasma cell dysplasia, plasmacytoma, plasma cell leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, isolated plasmacytoma, extramedullary plasmacytoma, osteosclerosing myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma.

[0329] [Other embodiments] The foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, but the illustrations and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entireties by reference.

[0330] [Equivalents and scope] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.

[0331] Articles such as "a," "an," and "the" may mean one or more, unless the contrary is indicated or otherwise clear from the context. A claim or description containing "or" between two or more members of a group is considered to be satisfied when one, more than one, or all of the group members are present, unless the contrary is indicated or otherwise clear from the context. A disclosure of a group containing "or" between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one member of the group is present, and embodiments in which all of the group members are present. For the sake of brevity, those embodiments are not individually described in detail herein, but it is understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

[0332] It is to be understood that the present disclosure encompasses all variations, combinations, and substitutions in which one or more limitations, elements, clauses, or descriptive terms from one or more of the claims or one or more relevant parts of the specification are introduced into another claim. For example, a claim that is dependent on another claim may be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, when a claim describes a composition, it is to be understood that the claim includes any method of making or using the composition according to any of the methods of making or using disclosed herein, or according to any method known in the art, if any, unless otherwise indicated or a contradiction or inconsistency would be apparent to a person skilled in the art.

[0333] When elements are presented as a list, e.g., in Markush group format, it is understood that all possible subgroups of the elements are also disclosed, and that any element or subgroup of elements can be deleted from the group. It is also noted that the term "comprising" is intended to be open, allowing for the inclusion of additional elements or steps. In general, when an embodiment, article, or method is described as comprising certain elements, features, or steps, it is understood that an embodiment, article, or method consisting of or consisting essentially of such elements, features, or steps is also provided. For the sake of brevity, the embodiments are not individually described in detail herein, but it is understood that each of these embodiments may be provided herein and specifically claimed or disclaimed.

[0334] When ranges are given, the endpoints are included. Moreover, unless otherwise indicated or otherwise clear from the context and / or the understanding of one of ordinary skill in the art, it should be understood that values ​​expressed as ranges can take any particular value within the stated range in some embodiments, up to one tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It should also be understood that, although the values ​​in each range are not specifically described herein individually for the sake of brevity, each of these values ​​is provided herein and can be specifically claimed or disclaimed. It should also be understood that, unless otherwise indicated or otherwise clear from the context and / or the understanding of one of ordinary skill in the art, values ​​expressed as ranges can take any subrange within the stated range, with the endpoints of the subranges being expressed to the same degree of precision as one tenth of the unit of the lower limit of the range. Where web sites are provided, URL addresses are provided as non-browser executable code and include the respective web address period within parentheses. The actual web address does not include the parentheses.

[0335] In addition, it should be understood that any particular embodiment of the present disclosure may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may be explicitly excluded from any one or more of the claims. Any embodiment, element, feature, use, or aspect of the disclosed compositions and / or methods may be excluded from any one or more of the claims. For the sake of brevity, not all of the embodiments in which one or more elements, features, purposes, or aspects are excluded are explicitly listed herein.

Claims

1. An antibody that specifically binds to transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), (i) heavy chain complementarity determining region 1 (CDR-H1), heavy chain complementarity determining region 2 (CDR-H2), and heavy chain complementarity determining region 3 (CDR-H3) of a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 1; and (ii) An antibody comprising a light chain variable region (VL) having a light chain complementarity determining region 1 (CDR-L1), a light chain complementarity determining region 2 (CDR-L2), and a light chain complementarity determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:

2.

2. The antibody, (i) CDR-H1 set forth in SEQ ID NO: 26, CDR-H2 set forth in SEQ ID NO: 27, and CDR-H3 set forth in SEQ ID NO: 28; CDR-L1 set forth in SEQ ID NO: 29, CDR-L2 set forth in SEQ ID NO: 30, and CDR-L3 set forth in SEQ ID NO: 31; (ii) CDR-H1 set forth in SEQ ID NO: 32, CDR-H2 set forth in SEQ ID NO: 33, and CDR-H3 set forth in SEQ ID NO: 34; CDR-L1 set forth in SEQ ID NO: 35, CDR-L2 set forth in SEQ ID NO: 36, and CDR-L3 set forth in SEQ ID NO: 31; or (iii) CDR-H1 set forth in SEQ ID NO: 37, CDR-H2 set forth in SEQ ID NO: 38, and CDR-H3 set forth in SEQ ID NO: 39; CDR-L1 set forth in SEQ ID NO: 40, CDR-L2 set forth in SEQ ID NO: 30, and CDR-L3 set forth in SEQ ID NO: 41 and the antibody has a K of 2 nM or less. D The antibody of claim 1 which binds to TACI at

3. The antibody of claim 1 or 2, wherein the antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (VL) comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:

2.

4. A polynucleotide encoding the antibody of any one of claims 1 to 3, or a vector comprising said polynucleotide.

5. A chimeric antigen receptor (CAR) polypeptide comprising an extracellular target binding domain, the extracellular target binding domain comprising a TACI binding domain, the TACI binding domain comprising the antibody or antigen-binding fragment thereof of any one of claims 1 to 3; and (a) the CAR polypeptide comprises a transmembrane domain and an intracellular signaling domain; (b) the CAR polypeptide comprises one or more costimulatory domains. (c) the TACI binding domain does not include APRIL, BAFF, CAMLG, or portions thereof; and / or (d) the TACI binding domain has a K of 2 nM or less. D A CAR polypeptide that binds to TACI at

6. the TACI binding domain comprises an anti-TACI single chain variable fragment (scFv), the anti-TACI scFv comprising a heavy chain variable region (VH) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:1, or the VH comprises the amino acid sequence of SEQ ID NO:1; and The CAR polypeptide of claim 5, wherein the anti-TACI scFv comprises a light chain variable region (VL) comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2, or wherein the VL comprises the amino acid sequence of SEQ ID NO:

2.

7. A CAR polypeptide described in claim 6, wherein VH is located at the N-terminus of VL, or VL is located at the N-terminus of VH.

8. A CAR polypeptide as described in claim 7, wherein VH and VL are linked via a linker sequence.

9. A CAR polypeptide described in claim 8, wherein the linker sequence comprises an amino acid sequence of SEQ ID NO: 14, 15, 16, 17 or 3.

10. (a) the TACI binding domain comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 4 or 5, or the TACI binding domain comprises the amino acid sequence of SEQ ID NO: 4 or 5; (b) the transmembrane domain comprises a hinge / transmembrane domain; (c) the intracellular signaling domain comprises an intracellular signaling domain of CD3ζ, CD3ε, or CD3θ; and / or (d) the costimulatory domain comprises a costimulatory domain of 4-1BB, CD28, CD27, ICOS, or OX40; The CAR polypeptide of claim 5 or 6.

11. The CAR polypeptide of claim 10, wherein the hinge / transmembrane domain comprises the hinge / transmembrane domain of an immunoglobulin-like protein, CD28, CD8, or 4-1BB.

12. A CAR polypeptide as described in claim 11, wherein the hinge / transmembrane domain is the hinge / transmembrane domain of CD8.

13. A CAR polypeptide described in claim 12, wherein the hinge / transmembrane domain is the hinge / transmembrane domain of CD8, and the hinge / transmembrane domain of CD8 has the amino acid sequence of SEQ ID NO:

7.

14. A CAR polypeptide described in claim 10, wherein the intracellular signaling domain comprises the intracellular signaling domain of CD3ζ.

15. A CAR polypeptide described in claim 14, wherein the intracellular signaling domain of CD3ζ comprises the amino acid sequence of SEQ ID NO:

9.

16. The CAR polypeptide described in claim 10, wherein the costimulatory domain includes a 4-1BB costimulatory domain.

17. The CAR polypeptide described in claim 16, wherein the costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO:

8.

18. 18. The CAR polypeptide of any one of claims 5 to 17, wherein the CAR polypeptide comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 10, 11, 12, or 13.

19. A CAR polypeptide described in any one of claims 5 to 18, wherein the CAR polypeptide has an amino acid sequence of SEQ ID NO: 10, 11, 12, or 13.

20. A CAR polypeptide described in any one of claims 5 to 19, wherein the second target is B-cell maturation antigen (BCMA) and the extracellular target binding domain comprises a ligand of the second target, or comprises an antibody or an antigen-binding fragment thereof.

21. An antibody, or a CAR polypeptide described in claim 19 or 20, wherein the antigen-binding fragment thereof is an scFv.

22. A CAR polypeptide described in claim 21, wherein the anti-BCMA scFv is located at the N-terminus of the anti-TACI scFv or the anti-TACI scFv is located at the N-terminus of the anti-BCMA scFv.

23. A CAR polypeptide described in claim 19, comprising an amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 22, 23 or 24.

24. 24. A mammalian cell comprising the CAR polypeptide of any one of claims 5 to 23, wherein the mammalian cell is an induced pluripotent stem cell (iPSC) or an immune cell.

25. A mammalian cell comprising the CAR polypeptide described in claim 24, wherein the immune cell is a T cell or a natural killer (NK) cell.

26. A mammalian cell comprising the CAR polypeptide described in claim 24, wherein the mammalian cell is a human cell.

27. ​​One or more of the following: (i) a CAR polypeptide according to any one of claims 5 to 23, a polynucleotide according to claim 4, and / or a mammalian cell according to any one of claims 24 to 26; and (ii) an antibody according to any one of claims 1 to 3; A pharmaceutical agent for treating a disease or disorder in a subject in need of treatment, comprising:

28. 28. The pharmaceutical of claim 27, wherein the disease or disorder is cancer, an autoimmune disease or disorder, or a plasma cell dyscrasia or disorder.

29. The pharmaceutical agent described in claim 28, wherein the cancer comprises cells expressing TACI.

30. The pharmaceutical composition described in claim 28, wherein the cancer is multiple myeloma.

31. The pharmaceutical composition of claim 27, wherein the subject is resistant to anti-BCMA therapy.

32. 29. The method of claim 28, wherein the autoimmune disease or disorder is characterized by high titers of antibodies that contribute to the autoimmune disorder.

33. The pharmaceutical composition of claim 28, wherein the autoimmune disease or disorder is graft rejection, graft-versus-host disease, or hemophilia with factor inhibitors.

34. The pharmaceutical composition described in claim 28, wherein the plasma cell disease or disorder is dysplasmocytosis, plasmacytoma, plasma cell leukemia, multiple myeloma, Waldenström's macroglobulinemia, solitary plasmacytoma, extramedullary plasmacytoma, osteosclerosing myeloma, heavy chain disease, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma.

Citation Information

Patent Citations

  • taci antibody and its uses

    JP2005533863A

  • High affinity fusion proteins and therapeutic and diagnostic methods for use

    US20050032175A1

  • Pharmaceutical composition comprising Anti-GRP78 antibody as active ingredient

    US20100041074A1

  • Antibodies that bind both BCMA and taci

    WO2002066516A2

  • Diagnosis and treatment of BAFF-mediated autoimmune diseases and cancer

    WO2004074511A1